


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405098" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405098</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405098</article-id><article-id pub-id-type="pmcid-ver">PMC12405098.1</article-id><article-id pub-id-type="pmcaid">12405098</article-id><article-id pub-id-type="pmcaiid">12405098</article-id><article-id pub-id-type="pmid">40897935</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03431-0</article-id><article-id pub-id-type="publisher-id">3431</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advances of androgen receptor in triple-negative breast cancer: from molecular mechanisms to clinical applications</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="L">Lange</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="H">Hao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chunyan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Y">Yue</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ren</surname><given-names initials="Q">Qinglan</given-names></name><address><email>renqlwu@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yu</surname><given-names initials="S">Shengnan</given-names></name><address><email>1334870996@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033vnzz93</institution-id><institution-id institution-id-type="GRID">grid.452206.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 417X</institution-id><institution>Department of Oncology, Laboratory of Immunity, Inflammation &amp; Cancer, </institution><institution>The First Affiliated Hospital of Chongqing Medical University, </institution></institution-wrap>Chongqing, 400016 China </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1677</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3431.pdf"/><abstract id="Abs1"><p id="Par1">Triple-negative breast cancer (TNBC) is a clinically aggressive malignancy with high heterogeneity at molecular and genetic levels, which characterized by the absence of effective therapeutic targets and marked resistance to conventional chemotherapy regimens. The androgen receptor (AR) is highly expressed by TNBC tumor cells and plays a vital role on tumor progression. With more research into AR signaling pathways and functions, AR-targeted therapy is becoming a promising treatment strategy. This review synthesizes emerging evidence in AR-related preclinical research and clinical outcomes, including monotherapy and combined strategies based on AR-targeted treatment. Through the comprehensive review, we hope to find novel therapeutic insights for TNBC.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Androgen receptor</kwd><kwd>Triple-negative breast cancer</kwd><kwd>Androgen receptor inhibitors</kwd><kwd>Combination treatment</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Outstanding Youth Science Fund Project of National Natural Science Foundation of China</institution></funding-source><award-id>Grant No. 82203007</award-id><principal-award-recipient><name name-style="western"><surname>Yu</surname><given-names>Shengnan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the China Postdoctoral Science Foundation</institution></funding-source><award-id>No.2023MD744162</award-id><principal-award-recipient><name name-style="western"><surname>Yu</surname><given-names>Shengnan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par48">Breast cancer is divided into four subtypes defined by hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status, including luminal A&#12289;luminal B&#160;&#12289;HER2<sup>+</sup> or HER2 enriched subtype and triple-negative breast cancer (TNBC) [<xref ref-type="bibr" rid="CR1">1</xref>]. TNBC refers to a subtype of breast cancer in which estrogen receptor (ER), progesterone receptor (PR) and HER2 are negative, accounting for approximately 10%&#8211;20% of all breast cancer diagnoses [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Unlike other breast cancer subtypes, TNBC patients don&#8217;t benefit from endocrine or HER2-targeted therapies [<xref ref-type="bibr" rid="CR4">4</xref>], it is a highly aggressive, malignant cancer with low survival rate and poor prognosis among breast cancers. In clinical practice, treatment primarily relies on surgery, chemotherapy, and immunotherapy [<xref ref-type="bibr" rid="CR5">5</xref>]. However, due to the aggressive nature of TNBC, a majority of patients are diagnosed at an advanced stage with distant metastases, rendering them ineligible for surgical intervention [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition, the high degree of tumor heterogeneity in TNBC contributes to an immunosuppressive tumor microenvironment (TME), resulting in limited response rates to immunotherapy [<xref ref-type="bibr" rid="CR7">7</xref>]. Consequently, TNBC is associated with poor prognosis, highlighting the urgent need to identify novel therapeutic targets. Currently, the Fudan classification is the most widely used subtyping system for TNBC [<xref ref-type="bibr" rid="CR8">8</xref>], including the luminal androgen receptor (LAR) subtype, driven by androgen receptor signaling pathways; the mesenchymal (MES) subtype, marked by the enrichment of growth factor signaling pathways; the immunomodulatory (IM) subtype, characterized by the significant tumor-infiltrating lymphocytes (TILs) and high expression of immune checkpoint molecules; and the basal-like immune-suppressed (BLIS) subtype, known for activating the cell cycle and DNA repair pathways when immune response genes are downregulated. The LAR subtype accounts for approximately 15%&#8211;30% of all TNBC cases and is characterized by high expression of androgen receptor (AR) proteins [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. This article primarily reviews the recent advancements in AR-related research for TNBC, aiming to provide novel perspectives and potential therapeutic strategies for TNBC.</p></sec><sec id="Sec2"><title>The function and signaling pathways of AR</title><p id="Par49">AR is primarily located in the nucleus of target cells and belongs to the steroid receptor family. Unbound AR primarily resides in the cytoplasm, where it remains inactive by associating with heat shock proteins (HSPs), which stabilize AR in a conformation that facilitates ligand binding [<xref ref-type="bibr" rid="CR12">12</xref>]. In the presence of androgens such as testosterone and dihydrotestosterone, these hormones cross the cell membrane, inducing a conformational change in AR that leads to its dissociation from HSPs and the formation of AR homodimers, thereby activating AR. The activated AR then translocates into the nucleus, where it binds to androgen response elements (AREs) regulates the transcription of target genes [<xref ref-type="bibr" rid="CR13">13</xref>]. Under physiological conditions, AR mediates the effects of androgens, such as testosterone and dihydrotestosterone, in regulating the development of male external genitalia and the formation of secondary sexual characteristics, while also promoting prostate development and maintaining its function [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In females, androgens promote the conversion of primary follicles to secondary follicles through the AR, and work in conjunction with gonadotropins to regulate estrogen synthesis [<xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, in ER&#945;&#8201;+&#8201;breast tissue, activation of the AR can antagonize the proliferative effects of estrogen, thereby reducing the risk of tumor development [<xref ref-type="bibr" rid="CR17">17</xref>]. However, AR can also control gene transcription through this pathway, helping cells evade apoptosis and promoting proliferation, thereby facilitating tumorigenesis [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, as a nuclear transcription factor, AR can promote tumorigenesis in TNBC by regulating lncRNAs such as SOX2-OT [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par50">AR can also mediate rapid signal transduction through non-genomic pathways, thereby influencing cell proliferation, survival, and metabolism [<xref ref-type="bibr" rid="CR20">20</xref>]. The activation of AR can directly up-regulate the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway components (such as p-AKT and PI3K subunits) through phosphorylation modification, and the activation of PI3K/AKT can feedback on enhancing the stability or transcriptional activity of AR [<xref ref-type="bibr" rid="CR21">21</xref>]. In TNBC, AR activation of this pathway can enhance the survival and proliferation of tumor cells, resulting in poor prognosis for TNBC patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Activation of AR also can promote the cascade reaction of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway, with ERK further enhancing AR's transcriptional activity by phosphorylating specific sites (such as Ser81) [<xref ref-type="bibr" rid="CR23">23</xref>]. This allows AR signaling to be driven even in the absence of androgens, promoting cell proliferation and migration [<xref ref-type="bibr" rid="CR24">24</xref>]. In castration-resistant prostate cancer (CRPC), AR overexpression or mutation can lead to sustained activation of ERK, promoting tumor cell survival in an androgen-deprived environment [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In melanoma, the androgen-AR axis, by activating the MAPK/ERK pathway, may explain the higher incidence in male patients [<xref ref-type="bibr" rid="CR27">27</xref>]. In TNBC, the cross-activation of AR and the MAPK/ERK pathway can synergistically promote tumor progression and may also contribute to resistance to anti-androgen therapy [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Upon activation, AR can upregulate cyclin D1 expression, promoting the formation of the cyclin D-cyclin-dependent kinase 4 and 6 (cyclin D-CDK4/6) complex. This complex, in turn, phosphorylates the retinoblastoma protein (Rb), leading to the release of the transcription factor E2F, which drives the transition from the G1 to S phase of the cell cycle [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. However, in LAR TNBC, AR signaling drives tumor cell proliferation by activating the cyclin D-CDK4/6 axis [<xref ref-type="bibr" rid="CR32">32</xref>]. Other studies have shown that AR can form a complex with sarcoma (SRC), and rapidly activate the SRC/PI3K signaling pathway by activating the SRC substrate focal adhesion kinase (FAK) and recruiting the PI3K regulatory subunit P85&#945;, thereby making TNBC more aggressive [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. AR-related pathways are presented in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Overview of AR Signaling and Its Crosstalk with Other Pathways in TNBC (created by Figdraw.com)<bold>.</bold> In the androgen receptor (AR) signaling cascade, androgens activate AR and promote its translocation into the nucleus, where it binds to androgen response elements (AREs) on target genes to regulate transcriptional activity. This activation contributes to increased cell proliferation and survival. In addition, activated AR engages in extensive crosstalk with several oncogenic pathways&#8212;including PI3K/AKT/mTOR, MAPK/ERK, cyclin D&#8211;CDK4/6, and SRC/FAK&#8212;thereby further enhancing tumor cell proliferation, survival, and metabolic functions. In schematic representations, black arrows indicate signal activation, and orange arrows denote promotion. A: androgen; DHT: dihydrotestosterone</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12672_2025_3431_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec3"><title>AR expression in TNBC and its impact on imaging</title><sec id="Sec4"><title>AR detection and its expression in TNBC</title><p id="Par51">Currently, the determination of AR positivity in tumor cells prefominantly relies on the percentage of nuclear staining assessed through immunohistochemistry (IHC) [<xref ref-type="bibr" rid="CR35">35</xref>]. In clinical studies, AR positivity is typically defined as nuclear staining&#8201;&#8805;&#8201;1% or 10% [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, the absence of standardized criteria for AR positivity has led to significant variability in reported AR expression levels across TNBC tissues in different studies. Emerging evidence suggested that AR expression in TNBC ranges from 12 to 55% [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. One study has shown AR expression as high as 80% in some TNBC cohorts, with the presence of AR splice variants (AR-SVs, approximately 20%) and it also confirmed that AR-SV promotes aggressive TNBC growth [<xref ref-type="bibr" rid="CR10">10</xref>]. All of the above evidence suggests the potential importance of AR in this breast cancer subtype.</p><p id="Par52">To address the inherent limitations of IHC&#8212;such as interobserver variability and limited sensitivity&#8212;molecular strategies guided by biomarkers are being increasingly adopted to enhance the identification of AR-positive TNBC [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. These platforms facilitate a more nuanced characterization of AR-driven biology, thereby supporting improved patient stratification and aiding in the selection of candidates most likely to respond to AR-targeted treatments.</p></sec><sec id="Sec5"><title>The impact of AR expression on imaging</title><p id="Par53">Ultrasound, mammography, and magnetic resonance imaging (MRI) play crucial roles in the diagnosis, staging, and treatment decision-making for TNBC. Studies have shown that the expression status of AR affects the tumor's imaging characteristics in TNBC patients [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>] (Table&#160;<xref rid="Tab1" ref-type="table">1</xref><bold>, </bold>Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Comparison of AR expression in three imaging features</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">AR Expression</th><th align="left" colspan="3" rowspan="1">Image</th></tr><tr><th align="left" colspan="1" rowspan="1">Two-dimensional ultrasound</th><th align="left" colspan="1" rowspan="1">Mammography</th><th align="left" colspan="1" rowspan="1">MRI</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AR-positive</td><td align="left" colspan="1" rowspan="1"><p>Irregular Morphology</p><p>Blurred boundaries</p><p>Echo halo</p><p>Rear echo attenuation</p></td><td align="left" colspan="1" rowspan="1"><p>Irregular morphology</p><p>Blurry edges</p><p>calcify</p></td><td align="left" colspan="1" rowspan="1"><p>Irregular Morphology</p><p>No reinforcement</p></td></tr><tr><td align="left" colspan="1" rowspan="1">AR-negative</td><td align="left" colspan="1" rowspan="1"><p>Clear boundaries,</p><p>Round or oval</p></td><td align="left" colspan="1" rowspan="1"><p>Pattern rules</p><p>Most are not calcified</p></td><td align="left" colspan="1" rowspan="1">Round or oval</td></tr></tbody></table></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>The Impact of AR Expression on Imaging. <bold>A</bold> two-dimensional ultrasound; <bold>B</bold> mammography; <bold>C</bold> MRI</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12672_2025_3431_Fig2_HTML.jpg"/></fig></p><p id="Par54">In two-dimensional ultrasound, research has demonstrated that AR-positive patients frequently exhibit irregularly shaped masses with poorly defined margins or spiculated contours, often accompanied by a hypoechoic halo and posterior acoustic shadowing [<xref ref-type="bibr" rid="CR44">44</xref>]. In contrast, AR-negative patients tend to exhibit breast masses with well-defined, round or oval shapes [<xref ref-type="bibr" rid="CR45">45</xref>]. Posterior acoustic shadowing is determined by the ratio of fibrous tissue to glandular tissue within the tumor, reflecting the tumor's internal composition. When fibrous tissue predominates within the tumor, the sound wave penetration is reduced, leading to posterior acoustic shadowing, which is considered indicative of low-grade malignant tumors [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. So patients with AR-positive tend to have a better prognosis.</p><p id="Par55">M&#252;ller&#8217;s study on mammography proved that AR-positive TNBC tends to present as irregularly shaped masses with poorly defined borders or calcifications, whereas AR-negative TNBC is less frequently associated with these features and more commonly appears as non-calcified, simple masses [<xref ref-type="bibr" rid="CR48">48</xref>]. The lower histological grade and slower growth rate may allow surrounding tissues time for stromal interactions, which could be associated with the spiculated appearance of the mass [<xref ref-type="bibr" rid="CR49">49</xref>], suggesting that AR-positive tumors may have a better prognosis.</p><p id="Par56">In MRI, a study found that AR-positive tumors are more likely to present as non-enhancing masses with poorly defined margins, compared to AR-negative tumors, which predominantly appear as round or oval masses [<xref ref-type="bibr" rid="CR42">42</xref>]. These findings are consistent with the morphological characteristics observed in breast ultrasound and mammography images. The imaging characteristics of AR-positive TNBC across three modalities (ultrasound, mammography, and MRI) suggest that these tumors may exhibit features typical of lower malignancy and a relatively favorable prognosis. Additionally, these imaging findings can contribute to the optimization of IHC testing panels for suspected TNBC cases, and also offer valuable insights for personalized treatment strategies in clinical practice.</p></sec></sec><sec id="Sec6"><title>The relationship between AR and prognosis in TNBC</title><p id="Par57">The association between AR expression and prognosis in TNBC remains controversial in current research. Some studies have shown that AR-positive patients exhibit longer median overall survival (OS) compared to their AR-negative conterparts, suggesting that AR expression may serve as a favorable prognostic factor for TNBC patients [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. A large-scale cohort study focusing on TNBC patients aged 75&#160;years and older found that AR-positive elderly patients exhibited significantly prolonged disease-free interval and reduced recurrence rates compared to age-matched AR-negative controls [<xref ref-type="bibr" rid="CR52">52</xref>]. These results suggest that AR positivity is a good predictor of prognosis. However, a study by Xu's team found that AR positivity in TNBC does not influence the survival time of patients [<xref ref-type="bibr" rid="CR53">53</xref>]. Another research conducted in India also demonstrated that AR expression appears to have no significant correlation with prognostic outcomes in TNBC [<xref ref-type="bibr" rid="CR54">54</xref>], which aligns with the findings reported by Xu et al. However, a study [<xref ref-type="bibr" rid="CR55">55</xref>] found that the presence of AR expression is tied to a worse prognosis in TNBC patients. Notably, TNBC patients with AR-positive exhibit an increased propensity for late-stage recurrence and higher mortality rates [<xref ref-type="bibr" rid="CR56">56</xref>]. One research revealed that AR-positive patients(defined as&#8201;&#8805;&#8201;1% nuclear AR staining) exhibited higher rates of recurrence or distant metastasis compared to AR-negative patients, suggesting that AR positivity may be associated with unfavorable prognosis in TNBC [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par58">The discrepancies between these studies may be attributed to factors such as relatively small sample sizes, varying follow-up durations, differences in AR measurement methods (such as variations in laboratory conditions, sources of AR antibodies, detection techniques, and result interpretation criteria), and lack of standardized thresholds for defining AR positivity. While most studies define AR positivity as&#8201;&#8805;&#8201;10%, some utilize lower thresholds (&#8805;&#8201;5% or&#8201;&#8805;&#8201;1%) to include more samples. Consequently, further research is needed to clarify the prognostic significance of AR in TNBC.</p></sec><sec id="Sec7"><title>Applications of AR inhibitors in TNBC</title><p id="Par59">An increasing number of studies indicate that AR has a significant impact on a variety of signaling pathways, promoting cell proliferation and tumor progression by interacting with multiple signaling cascades [<xref ref-type="bibr" rid="CR58">58</xref>&#8211;<xref ref-type="bibr" rid="CR60">60</xref>]. With the growing understanding of AR signaling and its regulatory role across multiple pathways, increasing attention has been directed toward AR as a potential therapeutic target [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR61">61</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. This is particularly relevant in TNBC, a subtype lacking effective targeted therapies, where AR inhibitors have demonstrated promising potential for both research and clinical application.</p><sec id="Sec8"><title>Monotherapy with AR inhibitors</title><p id="Par60">Early treatment of AR-positive TNBC primarily relies on monotherapy with AR inhibitors (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Bicalutamide, a nonsteroidal androgen receptor antagonist, binds to AR and inhibits its activation. A phase II study conducted in 2013 [<xref ref-type="bibr" rid="CR64">64</xref>] reported that after six months of bicalutamide treatment, the rate of clinical benefit (CBR) was recorded at 19%, while the median duration of progression-free survival (PFS) reached 12&#160;weeks. The results suggest that AR antagonists may provide an innovative treatment option for TNBC patients and offer a basis for future studies on AR-targeted therapies. Second-generation AR antagonist enzalutamide exhibits significantly stronger inhibitory effects than bicalutamide. In a phase II study, the investigators used enzalutamide to treat patients with locally advanced or metastatic AR-positive TNBC and evaluated its safety in these patients, with AR positivity defined as nuclear AR staining&#8201;&gt;&#8201;0% [<xref ref-type="bibr" rid="CR65">65</xref>]. The findings indicated disease-free survival (DFS) rates of 94%, 92%, and 80% at 1, 2, and 3&#160;years, respectively, although the median OS data remain undefined. Moreover, the occurrence of grade&#8201;&#8805;&#8201;3 treatment-related adverse events was minimal, suggesting that enzalutamide is an effective and safe treatment option for patients with advanced AR-positive TNBC. Abiraterone is a CYP17 inhibitor that reduces endogenous androgen production by inhibiting CYP17 activity to block the androgen synthesis pathway [<xref ref-type="bibr" rid="CR66">66</xref>]. A multicenter phase II clinical study revealed that the combined administration of abiraterone and prednisone resulted in a 20% CBR, an objective response rate (ORR) of 6.7%, and a median PFS of 2.8&#160;months [<xref ref-type="bibr" rid="CR67">67</xref>]. These results indicate that abiraterone induces a notable therapeutic response in individuals diagnosed with advanced AR-positive TNBC. Darolutamide is a new generation of non-steroidal androgen receptor antagonists with high binding affinity for androgen receptors and potent antagonistic activity. The study reported a CBR of 29% and a median PFS of 1.9&#160;months. The most common grade 3 adverse event was palmar-plantar erythrodysesthesia syndrome. Notably, patients with high AR activity exhibited a CBR of 61%, whereas those with low AR activity had a CBR of only 10%, implying that increased AR activity in tumors enhances their responsiveness to darolutamide [<xref ref-type="bibr" rid="CR68">68</xref>]. These studies collectively indicate that AR inhibitors exhibit promising efficacy in the treatment of TNBC.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Monotherapy with AR Inhibitors (created by Figdraw.com). CYP17 lyase inhibitors, such as abiraterone, suppress androgen biosynthesis by inhibiting key enzymatic steps in steroidogenesis. In addition, AR antagonists, including bicalutamide, enzalutamide, and darolutamide, block the binding of androgens to the AR, thereby disrupting receptor activation and downstream signaling. These agents collectively inhibit the AR signaling axis and represent promising therapeutic strategies for AR-positive cancers</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12672_2025_3431_Fig3_HTML.jpg"/></fig></p><p id="Par61">However, given the pronounced heterogeneity of TNBC, monotherapy may not sufficiently address the diverse clinical needs of patients. Consequently, researchers have increasingly explored the potential of combining AR inhibitors with other therapeutic agents for the treatment of TNBC (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>), leading to the initiation of numerous clinical and preclinical studies.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Combination Therapy with AR Inhibitors (created by Figdraw.com). <bold>A</bold> Combined with taxanes to overcome AR-induced chemoresistance via P-glycoprotein upregulation. <bold>B</bold> Co-treatment with PI3K or CDK4/6 inhibitors enhances therapeutic efficacy. <bold>C</bold> Synergy with immune checkpoint inhibitors boosts immune response. <bold>D</bold> HDAC inhibitors may alter chromatin structure and improve treatment outcomes. In the schematic, orange/red arrows indicate activation or upregulation, green arrows show drug targets, purple arrows represent inhibition, and black arrows depict pathway activation</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="12672_2025_3431_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>AR-inhibitor based combination therapy</title><sec id="Sec10"><title>AR inhibitors&#8201;+&#8201;chemotherapy</title><p id="Par62">Taxane-based drugs, including albumin-bound paclitaxel, paclitaxel, and docetaxel, are a class of diterpenoid alkaloid compounds with significant antitumor activity [<xref ref-type="bibr" rid="CR69">69</xref>]. As first-line chemotherapeutic agents, they primarily induce tumor cell apoptosis by disrupting mitosis, making them widely utilized in breast cancer treatment [<xref ref-type="bibr" rid="CR70">70</xref>]. These agents exert their antitumor effects by binding to &#946;-tubulin, stabilizing microtubules, and preventing their depolymerization, thereby disrupting mitotic spindle assembly and ultimately inhibiting tumor cell division [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) transporter family, actively exports chemotherapeutic agents such as paclitaxel out of the cell via ATP hydrolysis [<xref ref-type="bibr" rid="CR73">73</xref>]. This process reduces intracellular drug accumulation, diminishes antitumor efficacy, and ultimately contributes to the development of paclitaxel resistance [<xref ref-type="bibr" rid="CR74">74</xref>]. In AR-positive TNBC, activation of the AR signaling pathway may indirectly promote the expression of P-gp [<xref ref-type="bibr" rid="CR75">75</xref>]. Consequently, AR inhibitors can suppress the expression or activity of P-gp by targeting AR and its splice variants, such as AR-SV, thereby reducing paclitaxel efflux and enhancing its cytotoxicity [<xref ref-type="bibr" rid="CR76">76</xref>]. As early as 2017, a preclinical study demonstrated that enzalutamide could enhance the efficacy of chemotherapy, and its concurrent use with chemotherapeutic agents was associated with a reduced risk of recurrence [<xref ref-type="bibr" rid="CR77">77</xref>]. A recent phase II trial evaluated the feasibility of enzalutamide in combination with weekly paclitaxel (80&#160;mg/m<sup>2</sup>) as neoadjuvant therapy for LAR-subtype TNBC. The study enrolled 24 patients with early-stage TNBC who exhibited suboptimal response to paclitaxel monotherapy [<xref ref-type="bibr" rid="CR78">78</xref>]. The primary endpoint was the composite rate of favorable clinical response, while secondary endpoints included event-free survival (EFS) and OS. Preliminary findings demonstrated that 42% of patients showed a clinical benefit, with a pathological complete response (pCR) rate of 25% [<xref ref-type="bibr" rid="CR78">78</xref>]. The median EFS was 45.3&#160;months, with 48-month EFS and OS rates of 33.4% and 62.9%, respectively; median OS had not yet been reached. Notably, no significant adverse events were reported during the study [<xref ref-type="bibr" rid="CR78">78</xref>]. This trial demonstrated that the combination of an AR inhibitor with paclitaxel significantly enhanced cytotoxic activity against TNBC cells, while maintaining a favorable safety profile. Subsequently, the trial registered under <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04947189">NCT04947189</ext-link> expanded its sample size and enrolled a total of 65 patients with AR-positive TNBC. Preliminary laboratory data from this study suggest that the combination of seviteronel (a small-molecule compound that dually targets the AR and CYP17 lyase) and docetaxel may improve survival in patients with metastatic AR-positive TNBC [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Although final results have not yet been published, the findings are anticipated to provide important evidence supporting the feasibility and safety of combining AR inhibitors with chemotherapy in this patient population.</p></sec><sec id="Sec11"><title>AR inhibitors&#8201;+&#8201;targeted therapy</title><p id="Par63">Approximately 50&#8211;70% TNBC harbor alterations in the PI3K/AKT/mTOR signaling pathway, such as PIK3CA mutations or loss of the tumor suppressor gene PTEN, resulting in pathway hyperactivation that promotes cell survival, proliferation, and resistance to chemotherapy [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. In AR-positive TNBC, the incidence of PIK3CA mutations is relatively high, ranging from approximately 16.3% to 38%, which is significantly greater than that observed in other TNBC subtypes and this molecular feature may render TNBCs with high AR expression more responsive to therapies targeting the PI3K/AKT/mTOR pathway [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. In vitro studies have shown that the combination of AR inhibitors (such as enzalutamide) with PI3K/mTOR inhibitors (like BEZ235) exhibits enhanced antiproliferative effects, particularly in AR-positive TNBC cells [<xref ref-type="bibr" rid="CR85">85</xref>]. The TBCRC032 trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02457910">NCT02457910</ext-link>) is a multicenter, randomized phase Ib/II study that plays a pivotal role in evaluating the efficacy of enzalutamide in combination with the PI3K inhibitor taselisib in patients with metastatic AR-positive TNBC. The results revealed that the combination therapy with enzalutamide and taselisib achieved a CBR of 35.7%, significantly higher than the 25% CBR observed with enzalutamide monotherapy. This combination regimen was well tolerated, with the main adverse events being hyperglycemia and rash. The trial was the first to confirm the safety of enzalutamide combined with taselisib and demonstrated significant clinical benefit in the AR-positive/PTEN-deficient subgroup [<xref ref-type="bibr" rid="CR86">86</xref>]. The 2016-0538 trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03207529">NCT03207529</ext-link>) explored the efficacy and adverse effects of the PI3K inhibitor apelisib in combination with enzalutamide in patients with advanced AR- and PTEN-positive TNBC. Preliminary results from the trial indicated that at 16&#160;weeks, the partial response rate was 6.7%, the disease stability rate was 26.7%, and the progression rate was 60%. The median OS was 19.4&#160;months, and the median PFS was 2.07&#160;months [<xref ref-type="bibr" rid="CR87">87</xref>]. The final results of this trial have yet to be published, but these initial data provide valuable insights into the potential efficacy and safety of this combination regimen for treating AR/PTEN-positive TNBC. Further trials are needed to fully assess its therapeutic potential. Current clinical trials have focused on combining PI3K inhibitors with AR inhibitors to treat AR-positive TNBC. Future studies may design clinical trials exploring the combination of AR inhibitors with AKT inhibitors or mTOR inhibitors to comprehensively assess the therapeutic efficacy of AR inhibition in conjunction with targeting this pathway.</p><p id="Par64">CDK4/6 inhibitors (such as ribociclib and palbociclib) block the phosphorylation of the Rb protein, thereby inhibiting the G1/S cell cycle transition. AR inhibitors (such as enzalutamide) may further suppress the expression of AR-driven cell cycle&#8211;related genes. The combination of these agents has the potential to enhance cell cycle arrest through complementary mechanisms [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Preclinical studies have demonstrated that AR inhibitors can enhance the cytostatic effects of CDK4/6 inhibitors, leading to reduced migration, invasion, and clonogenic capacity of TNBC cells. Moreover, this combination exhibits a synergistic antitumor effect [<xref ref-type="bibr" rid="CR89">89</xref>]. In vitro studies have shown that AR inhibition in AR-positive TNBC cell lines may downregulate upstream regulators of CDK4/6, such as cyclin D1, thereby increasing sensitivity to CDK4/6 inhibitors [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. As a result, the combination of enzalutamide and ribociclib significantly suppressed cell proliferation and induced a more pronounced G1 phase arrest. Additionally, this combination therapy demonstrated superior cytotoxicity and more effectively inhibited tumor cell migration and invasion compared to enzalutamide monotherapy [<xref ref-type="bibr" rid="CR88">88</xref>]. In addition, researchers have evaluated the efficacy of seviteronel in combination with the CDK4/6 inhibitor abemaciclib in preclinical TNBC models. The results showed that the combination therapy more effectively inhibited tumor cell growth compared to abemaciclib alone [<xref ref-type="bibr" rid="CR32">32</xref>]. Building upon the promising results from preclinical studies, clinical trials are currently underway to evaluate the efficacy and safety of combining AR inhibitors with CDK4/6 inhibitors in AR-positive TNBC patients. For instance, a multicenter, single-arm phase II trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03090165">NCT03090165</ext-link>) has enrolled 58 patients to assess the efficacy of ribociclib in combination with bicalutamide in advanced AR-positive TNBC. Currently, a phase II clinical trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02605486">NCT02605486</ext-link>) investigating the combination of palbociclib and bicalutamide in metastatic AR-positive TNBC patients is actively ongoing, with promising results anticipated [<xref ref-type="bibr" rid="CR90">90</xref>]. Additionally, another single-arm phase II trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06365788">NCT06365788</ext-link>) is investigating the safety and efficacy of abemaciclib combined with bicalutamide in 53 patients with locally advanced, unresectable, or metastatic AR-positive TNBC. As the results of these trials have not yet been published, further large-scale clinical studies are necessary to confirm the clinical benefits and safety of this combination therapy in TNBC patients.</p></sec><sec id="Sec12"><title>AR inhibitors&#8201;+&#8201;immunotherapy</title><p id="Par65">Programmed death-ligand 1 (PD-L1) is a cell membrane protein that binds to the PD-1 receptor expressed on T cells, thereby suppressing immune responses and promoting immune evasion [<xref ref-type="bibr" rid="CR91">91</xref>]. Recent reports suggest that TNBC is characterized by a highly immunosuppressive TME, which limits the efficacy of PD-1/PD-L1 inhibitors, such as atezolizumab, to only a subset of patients [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. AR inhibitors have been shown to reduce the infiltration of immunosuppressive cells, such as Tregs, improve the immune landscape of the TME, and enhance tumor immunogenicity [<xref ref-type="bibr" rid="CR94">94</xref>]. The AR signaling pathway may also promote immune evasion by regulating the expression of PD-L1 [<xref ref-type="bibr" rid="CR95">95</xref>]. These findings provide a theoretical basis for the combination of AR inhibitors and immune checkpoint inhibitors (ICIs). A phase II clinical trial which evaluated the combination of a selective androgen receptor modulator (SARM) enobosarm and the PD-L1 inhibitor pembrolizumab in AR-positive metastatic triple-negative breast cancer (mTNBC) patients included 16 participants, among whom 1 achieved complete response (CR), 1 had partial response (PR), 2 had stable disease (SD), and 12 experienced disease progression (PD) [<xref ref-type="bibr" rid="CR96">96</xref>]. The CBR at 16&#160;weeks was 25%, with a median follow-up time of 24.9&#160;months. PFS was 2.6&#160;months, OS was 25.5&#160;months, and adverse events were relatively infrequent [<xref ref-type="bibr" rid="CR96">96</xref>]. These results suggest that the combination of enobosarm and pembrolizumab has a good safety profile but only modest efficacy. Additionally, researchers are exploring two potentially effective strategies that combine bicalutamide with dual immune checkpoint inhibitors (nivolumab&#8201;+&#8201;ipilimumab) for the treatment of metastatic AR<sup>+</sup> HER2<sup>&#8722;</sup> breast cancer and TNBC. This phase II trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03650894">NCT03650894</ext-link>) aims to assess the safety and efficacy of alternative systemic combination therapies, although dual immune checkpoint inhibition (such as with ipilimumab) may increase the risk of immune-related adverse events (irAEs) [<xref ref-type="bibr" rid="CR97">97</xref>], the trial results are expected to offer greater clinical benefits for TNBC and may provide a new direction for its treatment.</p></sec><sec id="Sec13"><title>AR inhibitors&#8201;+&#8201;epigenetic therapy</title><p id="Par66">Histone deacetylases (HDACs) promote chromatin condensation by removing acetyl groups from histones, thereby suppressing the transcriptional activity of tumor suppressor genes such as p53 and RB, and contributing to tumorigenesis [<xref ref-type="bibr" rid="CR98">98</xref>]. In TNBC, the overexpression of HDAC subtypes such as HDAC1 and HDAC6 is significantly associated with tumor metastasis and chemoresistance [<xref ref-type="bibr" rid="CR99">99</xref>]. HDAC inhibitors exert their effects by blocking histone deacetylase activity, leading to increased histone acetylation, chromatin relaxation, and subsequent transcriptional activation of tumor suppressor genes such as p21 and p53 [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Moreover, HDAC inhibitors have been shown to downregulate the expression of AR and its splice variants, thereby enhancing the sensitivity of cancer cells to anti-androgen therapies [<xref ref-type="bibr" rid="CR102">102</xref>]. Previous studies have demonstrated that HDAC inhibitors exhibit promising antitumor activity across various cancer types [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. For instance, in hematologic malignancies, HDAC inhibitors have shown significant therapeutic efficacy, particularly in the treatment of lymphomas and leukemias [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. In breast cancer, a HDAC inhibitor entinostat has been shown to enhance sensitivity to endocrine therapy [<xref ref-type="bibr" rid="CR103">103</xref>]. Recently, researchers have explored the combination of enzalutamide with the histone deacetylase inhibitor chidamide (Chid) for the treatment of AR-positive TNBC cell lines. Preliminary findings suggest that this combination exerts anti-tumor activity by inducing cell cycle arrest at the G2/M phase, thereby inhibiting cell proliferation and migration. Subsequent transcriptomic analysis identified insulin receptor substrate 4 (IRS4) as a potential mediator in suppressing kirsten rat sarcoma viral oncogene homolog (KRAS) pathway activation. In this preclinical model, the combination therapy upregulated IRS4 expression, which in turn inhibited the PI3K/AKT/mTOR signaling pathway via disruption of KRAS signaling, ultimately leading to tumor growth suppression [<xref ref-type="bibr" rid="CR107">107</xref>]. Collectively, these studies highlight the promising therapeutic potential of this combination strategy in AR-positive TNBC. Ongoing efforts are focused on the design of relevant clinical trials, and the forthcoming results are anticipated to further elucidate its clinical value.</p></sec></sec></sec><sec id="Sec14"><title>Conclusions and future perspectives</title><p id="Par67">In the era of precision medicine, targeted therapies against AR provide new directions for the treatment of TNBC patients. Although the impact of AR expression on TNBC prognosis is still a subject of debate, it is believed that further investigation into the specific mechanisms of the AR signaling pathway will enhance understanding of TNBC development and progression, the AR expression status will have new implications for both prognosis and treatment. Currently, research on AR-targeted therapies for TNBC patients mainly focuses on phase I and II clinical trials. To further validate the efficacy and safety of AR inhibitors in TNBC patients, more phase III and IV clinical trials are needed. Several related clinical trials are currently underway (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>), and as research deepens on the use of these drugs either as monotherapies or in combination with other signaling pathway inhibitors, chemotherapy agents, and immunotherapies, AR-targeted drugs are expected to offer more clinical benefits for TNBC patients. However, a major challenge that persists is the lack of a standardized definition for AR positivity. IHC, the most commonly used method, suffers from variability in interpretation and inconsistent cut-off thresholds, leading to significant heterogeneity across studies. The absence of molecular or transcriptomic validation further complicates patient stratification. Establishing unified diagnostic criteria and incorporating multi-omic profiling may help address this issue and optimize patient selection for AR-targeted therapies.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Clinical trials of AR inhibitors in TNBC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Clinical Trial</th><th align="left" colspan="1" rowspan="1">Registration NO</th><th align="left" colspan="1" rowspan="1">State</th><th align="left" colspan="1" rowspan="1">Phase</th><th align="left" colspan="1" rowspan="1">AR&#8201;+&#8201;Definition</th><th align="left" colspan="1" rowspan="1">Target</th><th align="left" colspan="1" rowspan="1">Participant Arms</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Bicalutamide in Treatment of AR&#8201;+&#8201;TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03055312">NCT03055312</ext-link></td><td align="left" colspan="1" rowspan="1">Terminated</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">&#8807;10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><p>A: TPC</p><p>B: Bicalutamide</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Bicalutamide as A Treatment in AR-positive mTNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02348281">NCT02348281</ext-link></td><td align="left" colspan="1" rowspan="1">Terminated</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1">Bicalutamide</td></tr><tr><td align="left" colspan="1" rowspan="1">Safety and Efficacy Study of Enzalutamide in Patients With Advanced AR-positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01889238">NCT01889238</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1">Enzalutamide</td></tr><tr><td align="left" colspan="1" rowspan="1">Darolutamide or Capecitabine in Patients With&#160;AR-positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03383679">NCT03383679</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><p>A: Darolutamide</p><p>B: Capecitabine</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Bicalutamide in Treating Patients With TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02353988">NCT02353988</ext-link></td><td align="left" colspan="1" rowspan="1">Unknown</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><p>A: Bicalutamide</p><p>B: Physician's Choice</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR&#8201;+&#8201;TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02750358">NCT02750358</ext-link></td><td align="left" colspan="1" rowspan="1">Active, not recruiting</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;1%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1">Enzalutamide</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III</p><p>AR-positive TNBC</p></td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02689427">NCT02689427</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1">Enzalutamide&#8201;+&#8201;Paclitaxel</td></tr><tr><td align="left" colspan="1" rowspan="1">Alpelisib and Enzalutamide in Treating Patients With AR and PTEN-positive mBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03207529">NCT03207529</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;1%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>PI3K</p></td><td align="left" colspan="1" rowspan="1">Enzalutamide&#8201;+&#8201;Alpelisib</td></tr><tr><td align="left" colspan="1" rowspan="1">Taselisib and Enzalutamide in Treating Patients With AR TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02457910">NCT02457910</ext-link></td><td align="left" colspan="1" rowspan="1">Terminated</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>PI3K</p></td><td align="left" colspan="1" rowspan="1">Enzalutamide&#8201;+&#8201;Taselisib</td></tr><tr><td align="left" colspan="1" rowspan="1">Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With mBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06099769">NCT06099769</ext-link></td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><p>A: Enzalutamide</p><p>B: Enzalutamide&#8201;+&#8201;Mifepristone</p><p>C: TPC</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Seviteronel in Combination With Chemotherapy in AR-positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04947189">NCT04947189</ext-link></td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;0%</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1">Seviteronel&#8201;+&#8201;Dexamethasone&#8201;+&#8201;Docetaxel</td></tr><tr><td align="left" colspan="1" rowspan="1">Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02929576">NCT02929576</ext-link></td><td align="left" colspan="1" rowspan="1">Withdrawn</td><td align="left" colspan="1" rowspan="1">III</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">AR</td><td align="left" colspan="1" rowspan="1"><p>A: Enzalutamide&#8201;+&#8201;Paclitaxel</p><p>B: Enzalutamide followed by paclitaxel</p><p>Comparator:&#160;Paclitaxel</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Bicalutamide and Abemaciclib in Inoperable or Metastatic AR-positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06365788">NCT06365788</ext-link></td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;1%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>CDK4/6</p></td><td align="left" colspan="1" rowspan="1">Bicalutamide&#8201;+&#8201;Abemaciclib</td></tr><tr><td align="left" colspan="1" rowspan="1">Ribociclib and Bicalutamide in AR-positive TNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03090165">NCT03090165</ext-link></td><td align="left" colspan="1" rowspan="1">Recruiting</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;10%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>CDK4/6</p></td><td align="left" colspan="1" rowspan="1">Bicalutamide&#8201;+&#8201;Ribociclib</td></tr><tr><td align="left" colspan="1" rowspan="1">Palbociclib in Combination With Bicalutamide for the Treatment of&#160;AR-positive MBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02605486">NCT02605486</ext-link></td><td align="left" colspan="1" rowspan="1">Active, not recruiting</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;1%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>CDK4/6</p></td><td align="left" colspan="1" rowspan="1">Bicalutamide&#8201;+&#8201;Palbociclib</td></tr><tr><td align="left" colspan="1" rowspan="1">Pembrolizumab and Enobosarm in Treating Patients With&#160;AR-positive mTNBC</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02971761">NCT02971761</ext-link></td><td align="left" colspan="1" rowspan="1">Completed</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;50%</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>PD-L1</p></td><td align="left" colspan="1" rowspan="1">Enobosarm&#8201;+&#8201;Pembrolizumab</td></tr><tr><td align="left" colspan="1" rowspan="1">Nivolumab, Ipilimumab, and Bicalutamide in HER2 Negative Breast Cancer Patients</td><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03650894">NCT03650894</ext-link></td><td align="left" colspan="1" rowspan="1">Active, not recruiting</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><p>AR</p><p>PD-1</p></td><td align="left" colspan="1" rowspan="1">Nivolumab, Ipilimumab, and Bicalutamide</td></tr></tbody></table><table-wrap-foot><p>TPC: Taxotere, Carboplatin, Paclitaxel, Eribulin, Capecitabine, Gemcitabine</p></table-wrap-foot></table-wrap></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>TNBC</term><def><p id="Par2">Triple-negative breast cancer</p></def></def-item><def-item><term>AR</term><def><p id="Par3">Androgen receptor</p></def></def-item><def-item><term>HER2</term><def><p id="Par4">Human epidermal growth factor receptor-2</p></def></def-item><def-item><term>ER</term><def><p id="Par5">Estrogen receptor</p></def></def-item><def-item><term>PR</term><def><p id="Par6">Progesterone receptor</p></def></def-item><def-item><term>TME</term><def><p id="Par7">Tumor microenvironment</p></def></def-item><def-item><term>LAR</term><def><p id="Par8">Luminal androgen receptor</p></def></def-item><def-item><term>MES</term><def><p id="Par9">Mesenchymal</p></def></def-item><def-item><term>IM</term><def><p id="Par10">Immunomodulatory</p></def></def-item><def-item><term>TILs</term><def><p id="Par11">Tumor-infiltrating lymphocytes</p></def></def-item><def-item><term>BLIS</term><def><p id="Par12">Basal-like immune-suppressed</p></def></def-item><def-item><term>Hsps</term><def><p id="Par13">Heat shock proteins</p></def></def-item><def-item><term>AREs</term><def><p id="Par14">Androgen response elements</p></def></def-item><def-item><term>PI3K</term><def><p id="Par15">Phosphoinositide 3-kinase</p></def></def-item><def-item><term>AKT</term><def><p id="Par16">Protein kinase B</p></def></def-item><def-item><term>mTOR</term><def><p id="Par17">Mechanistic target of rapamycin</p></def></def-item><def-item><term>MAPK</term><def><p id="Par18">Mitogen-activated protein kinase</p></def></def-item><def-item><term>ERK</term><def><p id="Par19">Extracellular signal-regulated kinase</p></def></def-item><def-item><term>CDK4/6</term><def><p id="Par20">Cyclin-dependent kinase 4 and 6</p></def></def-item><def-item><term>CRPC</term><def><p id="Par21">Castration-resistant prostate cancer</p></def></def-item><def-item><term>Rb</term><def><p id="Par22">Retinoblastoma</p></def></def-item><def-item><term>SRC</term><def><p id="Par23">Sarcoma</p></def></def-item><def-item><term>FAK</term><def><p id="Par24">Focal adhesion kinase</p></def></def-item><def-item><term>IHC</term><def><p id="Par25">Immunohistochemistry</p></def></def-item><def-item><term>AR-SVs</term><def><p id="Par26">AR splice variants</p></def></def-item><def-item><term>MRI</term><def><p id="Par27">Magnetic resonance imaging</p></def></def-item><def-item><term>OS</term><def><p id="Par28">Overall survival</p></def></def-item><def-item><term>CBR</term><def><p id="Par29">Clinical benefit rate</p></def></def-item><def-item><term>DFS</term><def><p id="Par30">Disease-free survival</p></def></def-item><def-item><term>ORR</term><def><p id="Par31">Objective response rate</p></def></def-item><def-item><term>P-gp</term><def><p id="Par32">P-glycoprotein</p></def></def-item><def-item><term>ABC</term><def><p id="Par33">ATP-binding cassette</p></def></def-item><def-item><term>EFS</term><def><p id="Par34">Event-free survival</p></def></def-item><def-item><term>pCR</term><def><p id="Par35">Pathological complete response</p></def></def-item><def-item><term>ICIs</term><def><p id="Par36">Immune checkpoint inhibitors</p></def></def-item><def-item><term>mTNBC</term><def><p id="Par37">Metastatic triple-negative breast cancer</p></def></def-item><def-item><term>SARM</term><def><p id="Par38">Selective androgen receptor modulator</p></def></def-item><def-item><term>CR</term><def><p id="Par39">Complete response</p></def></def-item><def-item><term>PR</term><def><p id="Par40">Partial response</p></def></def-item><def-item><term>SD</term><def><p id="Par41">Stable disease</p></def></def-item><def-item><term>PD</term><def><p id="Par42">Disease progression</p></def></def-item><def-item><term>irAEs</term><def><p id="Par43">Immune-related adverse events</p></def></def-item><def-item><term>HDACs</term><def><p id="Par44">Histone deacetylases</p></def></def-item><def-item><term>Chid</term><def><p id="Par45">Chidamide</p></def></def-item><def-item><term>IRS4</term><def><p id="Par46">Insulin receptor substrate 4</p></def></def-item><def-item><term>KRAS</term><def><p id="Par47">Kirsten rat sarcoma viral oncogene homolog</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>LM searched the literatures and wrote the manuscript. HX, CW and YH searched the literatures and prepared the charts 1&#8211;4, QR and SY designed the study and revised the manuscript. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This review was supported by National Natural Science Foundation of China (Grant No. 82203007) and the China Postdoctoral Science Foundation (No.2023MD744162).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par68">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par69">All authors have read and approved the final manuscript for publication.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reghukumar</surname><given-names>SK</given-names></name><name name-style="western"><surname>Inkielewicz-Stepniak</surname><given-names>I</given-names></name></person-group><article-title>Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2025</year><volume>1880</volume><issue>2</issue><fpage>189276</fpage><pub-id pub-id-type="pmid">39921012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2025.189276</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Reghukumar SK, Inkielewicz-Stepniak I. Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles. Biochim Biophys Acta Rev Cancer. 2025;1880(2):189276.<pub-id pub-id-type="pmid">39921012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2025.189276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaudhri</surname><given-names>S</given-names></name></person-group><article-title>Recent update on IGF-1/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer</article-title><source>Pathol Res Pract</source><year>2024</year><volume>263</volume><fpage>155620</fpage><pub-id pub-id-type="pmid">39357179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2024.155620</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kumar S, Chaudhri S. Recent update on IGF-1/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer. Pathol Res Pract. 2024;263: 155620.<pub-id pub-id-type="pmid">39357179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2024.155620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedeljkovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Vuleti&#263;</surname><given-names>A</given-names></name><name name-style="western"><surname>Mirja&#269;i&#263; Martinovi&#263;</surname><given-names>K</given-names></name></person-group><article-title>Divide and conquer-targeted therapy for triple-negative breast cancer</article-title><source>Int J Mol Sci</source><year>2025</year><pub-id pub-id-type="pmid">40003864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26041396</pub-id><pub-id pub-id-type="pmcid">PMC11855393</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Nedeljkovi&#263; M, Vuleti&#263; A, Mirja&#269;i&#263; Martinovi&#263; K. Divide and conquer-targeted therapy for triple-negative breast cancer. Int J Mol Sci. 2025. 10.3390/ijms26041396.<pub-id pub-id-type="pmid">40003864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26041396</pub-id><pub-id pub-id-type="pmcid">PMC11855393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>MS</given-names></name><name name-style="western"><surname>Pant</surname><given-names>K</given-names></name><name name-style="western"><surname>Ali</surname><given-names>H</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>R</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>AA</given-names></name></person-group><article-title>Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC)</article-title><source>Curr Cancer Drug Targets</source><year>2025</year><volume>25</volume><issue>2</issue><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">39248064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0115680096343056240828190900</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Gupta G, Hussain MS, Pant K, Ali H, Thapa R, Bhat AA. Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC). Curr Cancer Drug Targets. 2025;25(2):108&#8211;12.<pub-id pub-id-type="pmid">39248064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0115680096343056240828190900</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>F</given-names></name></person-group><article-title>New strategies for the management of triple-negative breast cancer</article-title><source>Curr Opin Obstet Gynecol</source><year>2024</year><volume>36</volume><issue>1</issue><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">38170551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GCO.0000000000000927</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Riaz F. New strategies for the management of triple-negative breast cancer. Curr Opin Obstet Gynecol. 2024;36(1):40&#8211;4.<pub-id pub-id-type="pmid">38170551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GCO.0000000000000927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name><name name-style="western"><surname>Leng</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>TNBC molecular subtypes and potential detection targets for biological therapy indications</article-title><source>Carcinogenesis</source><year>2025</year><pub-id pub-id-type="pmid">39977309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgaf006</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Zhang Y, Li Q, Lan J, Xie G, Zhang G, Cui J, Leng P, Wang Y. TNBC molecular subtypes and potential detection targets for biological therapy indications. Carcinogenesis. 2025. 10.1093/carcin/bgaf006.<pub-id pub-id-type="pmid">39977309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgaf006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KM</given-names></name></person-group><article-title>Immune checkpoint blockades in triple-negative breast cancer: current state and molecular mechanisms of resistance</article-title><source>Biomedicines</source><year>2022</year><pub-id pub-id-type="pmid">35625867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10051130</pub-id><pub-id pub-id-type="pmcid">PMC9138553</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Kim H, Choi JM, Lee KM. Immune checkpoint blockades in triple-negative breast cancer: current state and molecular mechanisms of resistance. Biomedicines. 2022. 10.3390/biomedicines10051130.<pub-id pub-id-type="pmid">35625867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10051130</pub-id><pub-id pub-id-type="pmcid">PMC9138553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y-Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Suo</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K-D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y-R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><issue>3</issue><fpage>428</fpage><lpage>440.e425</lpage><pub-id pub-id-type="pmid">30853353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2019.02.001</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu K-D, Liu Y-R, Yu Y, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428-440.e425.<pub-id pub-id-type="pmid">30853353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2019.02.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Leon-Ferre</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sinnwell</surname><given-names>JP</given-names></name><name name-style="western"><surname>Zahrieh</surname><given-names>DM</given-names></name><name name-style="western"><surname>Suman</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>FO</given-names></name><name name-style="western"><surname>Asad</surname><given-names>S</given-names></name><name name-style="western"><surname>Stover</surname><given-names>DG</given-names></name><name name-style="western"><surname>Carey</surname><given-names>L</given-names></name><name name-style="western"><surname>Sikov</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response</article-title><source>NAR Cancer</source><year>2022</year><volume>4</volume><issue>2</issue><fpage>zcac018</fpage><pub-id pub-id-type="pmid">35734391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/narcan/zcac018</pub-id><pub-id pub-id-type="pmcid">PMC9204893</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Thompson KJ, Leon-Ferre RA, Sinnwell JP, Zahrieh DM, Suman VJ, Metzger FO, Asad S, Stover DG, Carey L, Sikov WM, et al. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 2022;4(2): zcac018.<pub-id pub-id-type="pmid">35734391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/narcan/zcac018</pub-id><pub-id pub-id-type="pmcid">PMC9204893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asemota</surname><given-names>S</given-names></name><name name-style="western"><surname>Effah</surname><given-names>W</given-names></name><name name-style="western"><surname>Young</surname><given-names>KL</given-names></name><name name-style="western"><surname>Holt</surname><given-names>J</given-names></name><name name-style="western"><surname>Cripe</surname><given-names>L</given-names></name><name name-style="western"><surname>Ponnusamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Thiyagarajan</surname><given-names>T</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>DJ</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><issue>12</issue><fpage>113461</fpage><pub-id pub-id-type="pmid">37979170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113461</pub-id><pub-id pub-id-type="pmcid">PMC10872270</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Asemota S, Effah W, Young KL, Holt J, Cripe L, Ponnusamy S, Thiyagarajan T, Hwang DJ, He Y, McNamara K, et al. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype. Cell Rep. 2023;42(12): 113461.<pub-id pub-id-type="pmid">37979170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113461</pub-id><pub-id pub-id-type="pmcid">PMC10872270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tong</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>CW</given-names></name><name name-style="western"><surname>Tam</surname><given-names>F</given-names></name><name name-style="western"><surname>Loong</surname><given-names>TC</given-names></name><name name-style="western"><surname>Tse</surname><given-names>GM</given-names></name></person-group><article-title>Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin</article-title><source>ESMO Open</source><year>2024</year><volume>9</volume><issue>4</issue><fpage>102993</fpage><pub-id pub-id-type="pmid">38613910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2024.102993</pub-id><pub-id pub-id-type="pmcid">PMC11024544</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hu H, Tong K, Tsang JY, Ko CW, Tam F, Loong TC, Tse GM. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin. ESMO Open. 2024;9(4): 102993.<pub-id pub-id-type="pmid">38613910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2024.102993</pub-id><pub-id pub-id-type="pmcid">PMC11024544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dotto</surname><given-names>GP</given-names></name><name name-style="western"><surname>Buckinx</surname><given-names>A</given-names></name><name name-style="western"><surname>&#214;zdemir</surname><given-names>BC</given-names></name><name name-style="western"><surname>Simon</surname><given-names>C</given-names></name></person-group><article-title>Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities</article-title><source>Nat Rev Cancer</source><year>2025</year><volume>25</volume><issue>2</issue><fpage>93</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">39587300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-024-00772-w</pub-id><pub-id pub-id-type="pmcid">PMC11947662</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dotto GP, Buckinx A, &#214;zdemir BC, Simon C. Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities. Nat Rev Cancer. 2025;25(2):93&#8211;108.<pub-id pub-id-type="pmid">39587300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-024-00772-w</pub-id><pub-id pub-id-type="pmcid">PMC11947662</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>CP</given-names></name><name name-style="western"><surname>Leung</surname><given-names>MH</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>US</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>H</given-names></name></person-group><article-title>Androgen receptor as an emerging feasible biomarker for breast cancer</article-title><source>Biomolecules</source><year>2022</year><pub-id pub-id-type="pmid">35053220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12010072</pub-id><pub-id pub-id-type="pmcid">PMC8774219</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">You CP, Leung MH, Tsang WC, Khoo US, Tsoi H. Androgen receptor as an emerging feasible biomarker for breast cancer. Biomolecules. 2022. 10.3390/biom12010072.<pub-id pub-id-type="pmid">35053220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12010072</pub-id><pub-id pub-id-type="pmcid">PMC8774219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodamoradi</surname><given-names>K</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K</given-names></name><name name-style="western"><surname>Arora</surname><given-names>H</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>R</given-names></name></person-group><article-title>Evaluation of androgen receptor markers in erectile dysfunction</article-title><source>Andrology</source><year>2024</year><volume>12</volume><issue>3</issue><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">37551851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/andr.13507</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Khodamoradi K, Campbell K, Arora H, Ramasamy R. Evaluation of androgen receptor markers in erectile dysfunction. Andrology. 2024;12(3):599&#8211;605.<pub-id pub-id-type="pmid">37551851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/andr.13507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Androgens and androgen receptor directly induce the thickening, folding, and vascularization of the seahorse abdominal dermal layer into a placenta-like structure responsible for male pregnancy via multiple signaling pathways</article-title><source>Int J Biol Macromol</source><year>2024</year><volume>279</volume><issue>Pt 1</issue><fpage>135039</fpage><pub-id pub-id-type="pmid">39197609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2024.135039</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang Y, Shi X, Shi M, Li J, Liu Q. Androgens and androgen receptor directly induce the thickening, folding, and vascularization of the seahorse abdominal dermal layer into a placenta-like structure responsible for male pregnancy via multiple signaling pathways. Int J Biol Macromol. 2024;279(Pt 1): 135039.<pub-id pub-id-type="pmid">39197609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2024.135039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>The effect of 3-Methyl-4-Nitrophenol on the early ovarian follicle development in mice by disrupting the clock genes expression</article-title><source>Chem Biol Interact</source><year>2022</year><volume>363</volume><fpage>110001</fpage><pub-id pub-id-type="pmid">35654127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2022.110001</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Fan S, Zhao X, Xie W, Yang X, Yu W, Tang Z, Chen Y, Yuan Z, Han Y, Sheng X, et al. The effect of 3-Methyl-4-Nitrophenol on the early ovarian follicle development in mice by disrupting the clock genes expression. Chem Biol Interact. 2022;363: 110001.<pub-id pub-id-type="pmid">35654127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2022.110001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiodo</surname><given-names>C</given-names></name><name name-style="western"><surname>Nocito</surname><given-names>MC</given-names></name><name name-style="western"><surname>Cormace</surname><given-names>A</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>S</given-names></name><name name-style="western"><surname>Sisci</surname><given-names>D</given-names></name><name name-style="western"><surname>Sirianni</surname><given-names>R</given-names></name><name name-style="western"><surname>Casaburi</surname><given-names>I</given-names></name><name name-style="western"><surname>And&#242;</surname><given-names>S</given-names></name><name name-style="western"><surname>Lanzino</surname><given-names>M</given-names></name></person-group><article-title>Androgens modulate Bcl-2 agonist of cell death (BAD) expression and function in breast cancer cells</article-title><source>Int J Mol Sci</source><year>2023</year><pub-id pub-id-type="pmid">37686282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241713464</pub-id><pub-id pub-id-type="pmcid">PMC10487823</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Morelli C, Chiodo C, Nocito MC, Cormace A, Catalano S, Sisci D, Sirianni R, Casaburi I, And&#242; S, Lanzino M. Androgens modulate Bcl-2 agonist of cell death (BAD) expression and function in breast cancer cells. Int J Mol Sci. 2023. 10.3390/ijms241713464.<pub-id pub-id-type="pmid">37686282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241713464</pub-id><pub-id pub-id-type="pmcid">PMC10487823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagare</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Garg</surname><given-names>P</given-names></name></person-group><article-title>AndroPred: an artificial intelligence-based model for predicting androgen receptor inhibitors</article-title><source>J Biomol Struct Dyn</source><year>2024</year><volume>42</volume><issue>14</issue><fpage>7340</fpage><lpage>7348</lpage><pub-id pub-id-type="pmid">37493402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2023.2239935</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gagare R, Sharma A, Garg P. AndroPred: an artificial intelligence-based model for predicting androgen receptor inhibitors. J Biomol Struct Dyn. 2024;42(14):7340&#8211;8.<pub-id pub-id-type="pmid">37493402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2023.2239935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Androgen receptor-induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p/CCR5 axis</article-title><source>J Biol Chem</source><year>2025</year><volume>301</volume><fpage>108428</fpage><pub-id pub-id-type="pmid">40118451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2025.108428</pub-id><pub-id pub-id-type="pmcid">PMC12017981</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hu Y, Bian J, Chen W, Shi J, Wei X, Du Y, Zhang W. Androgen receptor-induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p/CCR5 axis. J Biol Chem. 2025;301:108428.<pub-id pub-id-type="pmid">40118451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2025.108428</pub-id><pub-id pub-id-type="pmcid">PMC12017981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahiya</surname><given-names>V</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>G</given-names></name></person-group><article-title>Non-canonical androgen signaling pathways and implications in prostate cancer</article-title><source>Biochim Biophys Acta</source><year>2022</year><volume>1869</volume><issue>12</issue><fpage>119357</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbamcr.2022.119357</pub-id><pub-id pub-id-type="pmid">36100060</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dahiya V, Bagchi G. Non-canonical androgen signaling pathways and implications in prostate cancer. Biochim Biophys Acta. 2022;1869(12): 119357.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbamcr.2022.119357</pub-id><pub-id pub-id-type="pmid">36100060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raith</surname><given-names>F</given-names></name><name name-style="western"><surname>O'Donovan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lemos</surname><given-names>C</given-names></name><name name-style="western"><surname>Politz</surname><given-names>O</given-names></name><name name-style="western"><surname>Haendler</surname><given-names>B</given-names></name></person-group><article-title>Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>3</issue><fpage>2289</fpage><pub-id pub-id-type="pmid">36768610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032289</pub-id><pub-id pub-id-type="pmcid">PMC9917236</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Raith F, O&#8217;Donovan DH, Lemos C, Politz O, Haendler B. Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment. Int J Mol Sci. 2023;24(3):2289.<pub-id pub-id-type="pmid">36768610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032289</pub-id><pub-id pub-id-type="pmcid">PMC9917236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remy</surname><given-names>D</given-names></name><name name-style="western"><surname>Antoine-Bally</surname><given-names>S</given-names></name><name name-style="western"><surname>de Toqueville</surname><given-names>S</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>C</given-names></name><name name-style="western"><surname>Mac&#233;</surname><given-names>AS</given-names></name><name name-style="western"><surname>Champenois</surname><given-names>G</given-names></name><name name-style="western"><surname>Nemati</surname><given-names>F</given-names></name><name name-style="western"><surname>Brito</surname><given-names>I</given-names></name><name name-style="western"><surname>Raynal</surname><given-names>V</given-names></name><name name-style="western"><surname>Priya</surname><given-names>A</given-names></name><etal/></person-group><article-title>TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression</article-title><source>Dev Cell</source><year>2025</year><volume>60</volume><issue>7</issue><fpage>1018</fpage><lpage>1035.e1018</lpage><pub-id pub-id-type="pmid">39729986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2024.12.005</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Remy D, Antoine-Bally S, de Toqueville S, Jolly C, Mac&#233; AS, Champenois G, Nemati F, Brito I, Raynal V, Priya A, et al. TFEB triggers a matrix degradation and invasion program in triple-negative breast cancer cells upon mTORC1 repression. Dev Cell. 2025;60(7):1018-1035.e1018.<pub-id pub-id-type="pmid">39729986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2024.12.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Y</given-names></name></person-group><article-title>Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor</article-title><source>Clin Transl Med</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>e1531</fpage><pub-id pub-id-type="pmid">38214432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1531</pub-id><pub-id pub-id-type="pmcid">PMC10785194</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cai Y, Chen M, Gong Y, Tang G, Shu Z, Chen J, Zhou H, He Y, Long Z, Gan Y. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor. Clin Transl Med. 2024;14(1): e1531.<pub-id pub-id-type="pmid">38214432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1531</pub-id><pub-id pub-id-type="pmcid">PMC10785194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>An</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression</article-title><source>Acta Biochim Biophys Sin</source><year>2022</year><volume>54</volume><issue>10</issue><fpage>1431</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">36017891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3724/abbs.2022111</pub-id><pub-id pub-id-type="pmcid">PMC9827993</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Xiao B, Zhang Y, Lu Z, Chen W, An Y, Zu G, Xu X, Wu D, Yang H, Qin Y, et al. A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression. Acta Biochim Biophys Sin. 2022;54(10):1431&#8211;40.<pub-id pub-id-type="pmid">36017891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3724/abbs.2022111</pub-id><pub-id pub-id-type="pmcid">PMC9827993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Labaf</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Ting</surname><given-names>L</given-names></name><name name-style="western"><surname>Karno</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Patalano</surname><given-names>S</given-names></name><name name-style="western"><surname>Macoska</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zarringhalam</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><etal/></person-group><article-title>Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>1021845</fpage><pub-id pub-id-type="pmid">36408179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.1021845</pub-id><pub-id pub-id-type="pmcid">PMC9669968</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Labaf M, Li M, Ting L, Karno B, Zhang S, Gao S, Patalano S, Macoska JA, Zarringhalam K, Han D, et al. Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Front Oncol. 2022;12:1021845.<pub-id pub-id-type="pmid">36408179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.1021845</pub-id><pub-id pub-id-type="pmcid">PMC9669968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>T</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moore</surname><given-names>DD</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name></person-group><article-title>A COP1-GATA2 axis suppresses AR signaling and prostate cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><issue>43</issue><fpage>e2205350119</fpage><pub-id pub-id-type="pmid">36251994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2205350119</pub-id><pub-id pub-id-type="pmcid">PMC9618149</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Shen T, Dong B, Meng Y, Moore DD, Yang F. A COP1-GATA2 axis suppresses AR signaling and prostate cancer. Proc Natl Acad Sci U S A. 2022;119(43): e2205350119.<pub-id pub-id-type="pmid">36251994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2205350119</pub-id><pub-id pub-id-type="pmcid">PMC9618149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>E</given-names></name><name name-style="western"><surname>Lester</surname><given-names>DK</given-names></name><name name-style="western"><surname>Fang</surname><given-names>B</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JO</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mockabee-Macias</surname><given-names>AT</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>V</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>KM</given-names></name><name name-style="western"><surname>White</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>1148</fpage><pub-id pub-id-type="pmid">38326303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45324-w</pub-id><pub-id pub-id-type="pmcid">PMC10850104</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Liu Q, Adhikari E, Lester DK, Fang B, Johnson JO, Tian Y, Mockabee-Macias AT, Izumi V, Guzman KM, White MG, et al. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun. 2024;15(1):1148.<pub-id pub-id-type="pmid">38326303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45324-w</pub-id><pub-id pub-id-type="pmcid">PMC10850104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>CP</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>H</given-names></name><name name-style="western"><surname>Man</surname><given-names>EPS</given-names></name><name name-style="western"><surname>Leung</surname><given-names>MH</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>US</given-names></name></person-group><article-title>Modulating the activity of androgen receptor for treating breast cancer</article-title><source>Int J Mol Sci</source><year>2022</year><pub-id pub-id-type="pmid">36499670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232315342</pub-id><pub-id pub-id-type="pmcid">PMC9739178</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">You CP, Tsoi H, Man EPS, Leung MH, Khoo US. Modulating the activity of androgen receptor for treating breast cancer. Int J Mol Sci. 2022. 10.3390/ijms232315342.<pub-id pub-id-type="pmid">36499670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232315342</pub-id><pub-id pub-id-type="pmcid">PMC9739178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Manai</surname><given-names>M</given-names></name><name name-style="western"><surname>Rampa</surname><given-names>DR</given-names></name><name name-style="western"><surname>Fuson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nakasone</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuntal</surname><given-names>BS</given-names></name><name name-style="western"><surname>Tripathy</surname><given-names>D</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>NT</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name></person-group><article-title>Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis</article-title><source>Mol Cancer Ther</source><year>2024</year><pub-id pub-id-type="pmid">39588561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0386</pub-id><pub-id pub-id-type="pmcid">PMC12104481</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xie X, Manai M, Rampa DR, Fuson JA, Nakasone ES, Pearson T, Kuntal BS, Tripathy D, Ueno NT, Lee J. Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis. Mol Cancer Ther. 2024. 10.1158/1535-7163.MCT-23-0386.<pub-id pub-id-type="pmid">39588561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0386</pub-id><pub-id pub-id-type="pmcid">PMC12104481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldaalis</surname><given-names>A</given-names></name><name name-style="western"><surname>Bengoechea-Alonso</surname><given-names>MT</given-names></name><name name-style="western"><surname>Ericsson</surname><given-names>J</given-names></name></person-group><article-title>The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>942386</fpage><pub-id pub-id-type="pmid">36091143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.942386</pub-id><pub-id pub-id-type="pmcid">PMC9451027</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Aldaalis A, Bengoechea-Alonso MT, Ericsson J. The SREBP-dependent regulation of cyclin D1 coordinates cell proliferation and lipid synthesis. Front Oncol. 2022;12: 942386.<pub-id pub-id-type="pmid">36091143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.942386</pub-id><pub-id pub-id-type="pmcid">PMC9451027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>N</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>D</given-names></name><name name-style="western"><surname>Alonso-Gordoa</surname><given-names>T</given-names></name><name name-style="western"><surname>Arranz Arija</surname><given-names>JA</given-names></name><name name-style="western"><surname>Colomba</surname><given-names>E</given-names></name><name name-style="western"><surname>Gravis</surname><given-names>G</given-names></name><name name-style="western"><surname>Mourey</surname><given-names>L</given-names></name><name name-style="western"><surname>Oudard</surname><given-names>S</given-names></name><name name-style="western"><surname>Fl&#233;chon</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></name><etal/></person-group><article-title>A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1</article-title><source>Clin Cancer Res</source><year>2024</year><volume>30</volume><issue>11</issue><fpage>2377</fpage><lpage>2383</lpage><pub-id pub-id-type="pmid">38512117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-3436</pub-id><pub-id pub-id-type="pmcid">PMC11145166</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fl&#233;chon A, Gonz&#225;lez M, et al. A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1. Clin Cancer Res. 2024;30(11):2377&#8211;83.<pub-id pub-id-type="pmid">38512117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-3436</pub-id><pub-id pub-id-type="pmcid">PMC11145166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chica-Parrado</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GM</given-names></name><name name-style="western"><surname>Uemoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Napolitano</surname><given-names>F</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D</given-names></name><name name-style="western"><surname>Bikorimana</surname><given-names>E</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KM</given-names></name><name name-style="western"><surname>Mendiratta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer</article-title><source>Cancer Lett</source><year>2024</year><volume>604</volume><fpage>217219</fpage><pub-id pub-id-type="pmid">39244005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2024.217219</pub-id><pub-id pub-id-type="pmcid">PMC11837982</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chica-Parrado MR, Kim GM, Uemoto Y, Napolitano F, Lin CC, Ye D, Bikorimana E, Fang Y, Lee KM, Mendiratta S, et al. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer. Cancer Lett. 2024;604: 217219.<pub-id pub-id-type="pmid">39244005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2024.217219</pub-id><pub-id pub-id-type="pmcid">PMC11837982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovannelli</surname><given-names>P</given-names></name><name name-style="western"><surname>Di Donato</surname><given-names>M</given-names></name><name name-style="western"><surname>Auricchio</surname><given-names>F</given-names></name><name name-style="western"><surname>Castoria</surname><given-names>G</given-names></name><name name-style="western"><surname>Migliaccio</surname><given-names>A</given-names></name></person-group><article-title>Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>4490</fpage><pub-id pub-id-type="pmid">30872694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-41016-4</pub-id><pub-id pub-id-type="pmcid">PMC6418124</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A. Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly. Sci Rep. 2019;9(1):4490.<pub-id pub-id-type="pmid">30872694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-41016-4</pub-id><pub-id pub-id-type="pmcid">PMC6418124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>N</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>VM</given-names></name><name name-style="western"><surname>Sayegh</surname><given-names>N</given-names></name><name name-style="western"><surname>Gebrael</surname><given-names>G</given-names></name><name name-style="western"><surname>Chigarira</surname><given-names>B</given-names></name><name name-style="western"><surname>Jo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Nussenzveig</surname><given-names>R</given-names></name><name name-style="western"><surname>Nordblad</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer</article-title><source>Prostate</source><year>2023</year><volume>83</volume><issue>16</issue><fpage>1602</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">37644774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pros.24618</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Tripathi N, Thomas VM, Sayegh N, Gebrael G, Chigarira B, Jo Y, Li H, Sahu KK, Nussenzveig R, Nordblad B, et al. Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer. Prostate. 2023;83(16):1602&#8211;9.<pub-id pub-id-type="pmid">37644774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pros.24618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name></person-group><article-title>Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer</article-title><source>Chin Med J</source><year>2024</year><volume>137</volume><issue>3</issue><fpage>338</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">38105538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002930</pub-id><pub-id pub-id-type="pmcid">PMC10836903</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Xu F, Xu K, Fan L, Li X, Liu Y, Yang F, Zhu C, Guan X. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer. Chin Med J. 2024;137(3):338&#8211;49.<pub-id pub-id-type="pmid">38105538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002930</pub-id><pub-id pub-id-type="pmcid">PMC10836903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubrava</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>PSP</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J</given-names></name><name name-style="western"><surname>Pringle</surname><given-names>J</given-names></name><name name-style="western"><surname>Westhuyzen</surname><given-names>J</given-names></name><name name-style="western"><surname>La Hera</surname><given-names>FG</given-names></name><name name-style="western"><surname>Shakespeare</surname><given-names>TP</given-names></name><name name-style="western"><surname>Sakalkale</surname><given-names>R</given-names></name><name name-style="western"><surname>Aherne</surname><given-names>NJ</given-names></name></person-group><article-title>Androgen receptor status in triple negative breast cancer: does it correlate with clinicopathological characteristics?</article-title><source>Breast Cancer</source><year>2023</year><volume>15</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">37197610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/BCTT.S405719</pub-id><pub-id pub-id-type="pmcid">PMC10184857</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Dubrava AL, Kyaw PSP, Newman J, Pringle J, Westhuyzen J, La Hera FG, Shakespeare TP, Sakalkale R, Aherne NJ. Androgen receptor status in triple negative breast cancer: does it correlate with clinicopathological characteristics? Breast Cancer. 2023;15:359&#8211;71.<pub-id pub-id-type="pmid">37197610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/BCTT.S405719</pub-id><pub-id pub-id-type="pmcid">PMC10184857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiraz</surname><given-names>U</given-names></name><name name-style="western"><surname>Rewcastle</surname><given-names>E</given-names></name><name name-style="western"><surname>Fykse</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lundal</surname><given-names>I</given-names></name><name name-style="western"><surname>Gudlaugsson</surname><given-names>EG</given-names></name><name name-style="western"><surname>Skaland</surname><given-names>I</given-names></name><name name-style="western"><surname>S&#248;iland</surname><given-names>H</given-names></name><name name-style="western"><surname>Baak</surname><given-names>JPA</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>EAM</given-names></name></person-group><article-title>Dual functions of Androgen Receptor overexpression in triple-negative breast cancer: a complex prognostic marker</article-title><source>Bioengineering</source><year>2025</year><pub-id pub-id-type="pmid">39851328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bioengineering12010054</pub-id><pub-id pub-id-type="pmcid">PMC11761274</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kiraz U, Rewcastle E, Fykse SK, Lundal I, Gudlaugsson EG, Skaland I, S&#248;iland H, Baak JPA, Janssen EAM. Dual functions of Androgen Receptor overexpression in triple-negative breast cancer: a complex prognostic marker. Bioengineering. 2025. 10.3390/bioengineering12010054.<pub-id pub-id-type="pmid">39851328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bioengineering12010054</pub-id><pub-id pub-id-type="pmcid">PMC11761274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>H</given-names></name><name name-style="western"><surname>Savage</surname><given-names>IV</given-names></name><name name-style="western"><surname>Okpechi</surname><given-names>SC</given-names></name><name name-style="western"><surname>Wright</surname><given-names>MK</given-names></name><name name-style="western"><surname>Matossian</surname><given-names>MD</given-names></name><name name-style="western"><surname>Collins-Burow</surname><given-names>BM</given-names></name><name name-style="western"><surname>Burow</surname><given-names>ME</given-names></name><name name-style="western"><surname>Alahari</surname><given-names>SK</given-names></name></person-group><article-title>Ceritinib is a novel triple negative breast cancer therapeutic agent</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>138</fpage><pub-id pub-id-type="pmid">35768871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-022-01601-0</pub-id><pub-id pub-id-type="pmcid">PMC9241294</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Dong S, Yousefi H, Savage IV, Okpechi SC, Wright MK, Matossian MD, Collins-Burow BM, Burow ME, Alahari SK. Ceritinib is a novel triple negative breast cancer therapeutic agent. Mol Cancer. 2022;21(1):138.<pub-id pub-id-type="pmid">35768871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-022-01601-0</pub-id><pub-id pub-id-type="pmcid">PMC9241294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8(+)T cell infiltration in triple-negative breast cancer</article-title><source>Transl Oncol</source><year>2024</year><volume>49</volume><fpage>102081</fpage><pub-id pub-id-type="pmid">39182361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2024.102081</pub-id><pub-id pub-id-type="pmcid">PMC11387711</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Pan Q, Ma D, Xiao Y, Ji K, Wu J. Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8(+)T cell infiltration in triple-negative breast cancer. Transl Oncol. 2024;49: 102081.<pub-id pub-id-type="pmid">39182361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2024.102081</pub-id><pub-id pub-id-type="pmcid">PMC11387711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Petrossian</surname><given-names>K</given-names></name><name name-style="western"><surname>Huang</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Saeki</surname><given-names>K</given-names></name><name name-style="western"><surname>Kanaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G</given-names></name><name name-style="western"><surname>Somlo</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer</article-title><source>J Steroid Biochem Mol Biol</source><year>2021</year><volume>206</volume><fpage>105791</fpage><pub-id pub-id-type="pmid">33271252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2020.105791</pub-id><pub-id pub-id-type="pmcid">PMC8820229</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Wang X, Petrossian K, Huang MJ, Saeki K, Kanaya N, Chang G, Somlo G, Chen S. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer. J Steroid Biochem Mol Biol. 2021;206: 105791.<pub-id pub-id-type="pmid">33271252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2020.105791</pub-id><pub-id pub-id-type="pmcid">PMC8820229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asleh</surname><given-names>K</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>N</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>TO</given-names></name></person-group><article-title>Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications</article-title><source>J Exp Clin Cancer Res</source><year>2022</year><volume>41</volume><issue>1</issue><fpage>265</fpage><pub-id pub-id-type="pmid">36050786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02476-1</pub-id><pub-id pub-id-type="pmcid">PMC9434975</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41(1):265.<pub-id pub-id-type="pmid">36050786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-022-02476-1</pub-id><pub-id pub-id-type="pmcid">PMC9434975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Candelaria</surname><given-names>RP</given-names></name><name name-style="western"><surname>Adrada</surname><given-names>BE</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>L</given-names></name><name name-style="western"><surname>Lane</surname><given-names>DL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>ML</given-names></name><name name-style="western"><surname>Arribas</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>GM</given-names></name><name name-style="western"><surname>Symmans</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Imaging features of triple-negative breast cancers according to androgen receptor status</article-title><source>Eur J Radiol</source><year>2019</year><volume>114</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">31005169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2019.03.017</pub-id><pub-id pub-id-type="pmcid">PMC6481318</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, et al. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019;114:167&#8211;74.<pub-id pub-id-type="pmid">31005169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2019.03.017</pub-id><pub-id pub-id-type="pmcid">PMC6481318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>TK</given-names></name><name name-style="western"><surname>Chae</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>SG</given-names></name><name name-style="western"><surname>Choi</surname><given-names>BO</given-names></name><name name-style="western"><surname>Park</surname><given-names>WC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name></person-group><article-title>Apobec-driven hypermutation in the lymphocyte-predominant group of triple-negative breast cancer</article-title><source>Lab Invest</source><year>2025</year><volume>105</volume><issue>7</issue><fpage>104165</fpage><pub-id pub-id-type="pmid">40199422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.labinv.2025.104165</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lee M, Lee A, Yoo TK, Chae BJ, Ahn SG, Choi BO, Park WC, Kim SH, Lee J, Kang J. Apobec-driven hypermutation in the lymphocyte-predominant group of triple-negative breast cancer. Lab Invest. 2025;105(7): 104165.<pub-id pub-id-type="pmid">40199422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.labinv.2025.104165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>N</given-names></name><name name-style="western"><surname>Han</surname><given-names>P</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer</article-title><source>Insights Imaging</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>46</fpage><pub-id pub-id-type="pmid">36929229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-023-01387-9</pub-id><pub-id pub-id-type="pmcid">PMC10020396</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhang X, Cui H, Hu N, Han P, Fan W, Wang P, Zuo X, Zhao D, Huang H, Li S, et al. Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer. Insights Imaging. 2023;14(1):46.<pub-id pub-id-type="pmid">36929229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-023-01387-9</pub-id><pub-id pub-id-type="pmcid">PMC10020396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>MS</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Song</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Park</surname><given-names>IA</given-names></name><name name-style="western"><surname>Noh</surname><given-names>DY</given-names></name><name name-style="western"><surname>Moon</surname><given-names>WK</given-names></name></person-group><article-title>Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression</article-title><source>Eur Radiol</source><year>2015</year><volume>25</volume><issue>2</issue><fpage>419</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">25224727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-014-3419-z</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bae MS, Park SY, Song SE, Kim WH, Lee SH, Han W, Park IA, Noh DY, Moon WK. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression. Eur Radiol. 2015;25(2):419&#8211;27.<pub-id pub-id-type="pmid">25224727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-014-3419-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title>Calcification, posterior acoustic, and blood flow: ultrasonic characteristics of triple-negative breast cancer</article-title><source>J Healthc Eng</source><year>2022</year><volume>2022</volume><fpage>9336185</fpage><pub-id pub-id-type="pmid">36199374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/9336185</pub-id><pub-id pub-id-type="pmcid">PMC9529478</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Wang K, Zou Z, Shen H, Huang G, Yang S. Calcification, posterior acoustic, and blood flow: ultrasonic characteristics of triple-negative breast cancer. J Healthc Eng. 2022;2022:9336185.<pub-id pub-id-type="pmid">36199374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/9336185</pub-id><pub-id pub-id-type="pmcid">PMC9529478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Role of ultrasonographic and clinicopathological characteristics in assessing stromal tumor-infiltrating lymphocyte density in triple-negative breast cancer</article-title><source>Balkan Med J</source><year>2024</year><volume>41</volume><issue>6</issue><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">39324418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4274/balkanmedj.galenos.2024.2024-7-26</pub-id><pub-id pub-id-type="pmcid">PMC11589214</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Li L, Li Y. Role of ultrasonographic and clinicopathological characteristics in assessing stromal tumor-infiltrating lymphocyte density in triple-negative breast cancer. Balkan Med J. 2024;41(6):469&#8211;75.<pub-id pub-id-type="pmid">39324418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4274/balkanmedj.galenos.2024.2024-7-26</pub-id><pub-id pub-id-type="pmcid">PMC11589214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#252;th</surname><given-names>U</given-names></name><name name-style="western"><surname>Varga</surname><given-names>Z</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>K</given-names></name><name name-style="western"><surname>Bjelic-Radisic</surname><given-names>V</given-names></name><name name-style="western"><surname>Fleisch</surname><given-names>M</given-names></name><name name-style="western"><surname>Tausch</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Elfgen</surname><given-names>C</given-names></name></person-group><article-title>Clinical imaging of the heterogeneous group of triple-negative breast cancer</article-title><source>Anticancer Res</source><year>2020</year><volume>40</volume><issue>4</issue><fpage>2125</fpage><lpage>2131</lpage><pub-id pub-id-type="pmid">32234905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.14171</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">M&#252;ller M, G&#252;th U, Varga Z, Reeve K, Bjelic-Radisic V, Fleisch M, Tausch CJ, Elfgen C. Clinical imaging of the heterogeneous group of triple-negative breast cancer. Anticancer Res. 2020;40(4):2125&#8211;31.<pub-id pub-id-type="pmid">32234905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.14171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JW</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Shi</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name></person-group><article-title>Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>9040</fpage><pub-id pub-id-type="pmid">29899425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-27222-6</pub-id><pub-id pub-id-type="pmcid">PMC5998063</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Li JW, Zhang K, Shi ZT, Zhang X, Xie J, Liu JY, Chang C. Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature. Sci Rep. 2018;8(1):9040.<pub-id pub-id-type="pmid">29899425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-27222-6</pub-id><pub-id pub-id-type="pmcid">PMC5998063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grosse</surname><given-names>C</given-names></name><name name-style="western"><surname>Noack</surname><given-names>P</given-names></name><name name-style="western"><surname>Grosse</surname><given-names>A</given-names></name><name name-style="western"><surname>Preuss</surname><given-names>CI</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>HK</given-names></name><name name-style="western"><surname>Gitter</surname><given-names>T</given-names></name><name name-style="western"><surname>Schrenk</surname><given-names>P</given-names></name><name name-style="western"><surname>Frauchiger-Heuer</surname><given-names>H</given-names></name><name name-style="western"><surname>Papassotiropoulos</surname><given-names>B</given-names></name><name name-style="western"><surname>Tausch</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prognostic impact of histological subtyping in triple-negative breast cancer</article-title><source>Hum Pathol</source><year>2024</year><volume>152</volume><fpage>105640</fpage><pub-id pub-id-type="pmid">39128557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humpath.2024.105640</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Grosse C, Noack P, Grosse A, Preuss CI, Schwarz HK, Gitter T, Schrenk P, Frauchiger-Heuer H, Papassotiropoulos B, Tausch C, et al. Prognostic impact of histological subtyping in triple-negative breast cancer. Hum Pathol. 2024;152: 105640.<pub-id pub-id-type="pmid">39128557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humpath.2024.105640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyalkin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Verevkina</surname><given-names>NO</given-names></name><name name-style="western"><surname>Alekseyenko</surname><given-names>OO</given-names></name><name name-style="western"><surname>Syvak</surname><given-names>LA</given-names></name></person-group><article-title>Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer</article-title><source>Exp Oncol</source><year>2020</year><volume>42</volume><issue>2</issue><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">32602289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.32471/exp-oncology.2312-8852.vol-42-no-2.14579</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Lyalkin SA, Verevkina NO, Alekseyenko OO, Syvak LA. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer. Exp Oncol. 2020;42(2):140&#8211;3.<pub-id pub-id-type="pmid">32602289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.32471/exp-oncology.2312-8852.vol-42-no-2.14579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>P</given-names></name><name name-style="western"><surname>Niu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name></person-group><article-title>Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis</article-title><source>Clin Breast Cancer</source><year>2020</year><volume>20</volume><issue>4</issue><fpage>e385</fpage><lpage>e396</lpage><pub-id pub-id-type="pmid">32139270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2020.01.002</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Xu M, Yuan Y, Yan P, Jiang J, Ma P, Niu X, Ma S, Cai H, Yang K. Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2020;20(4):e385&#8211;96.<pub-id pub-id-type="pmid">32139270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2020.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kucukzeybek</surname><given-names>BB</given-names></name><name name-style="western"><surname>Bayoglu</surname><given-names>IV</given-names></name><name name-style="western"><surname>Kucukzeybek</surname><given-names>Y</given-names></name><name name-style="western"><surname>Y&#305;ld&#305;z</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oflazoglu</surname><given-names>U</given-names></name><name name-style="western"><surname>Atahan</surname><given-names>MK</given-names></name><name name-style="western"><surname>Taskaynatan</surname><given-names>H</given-names></name><name name-style="western"><surname>Alacacioglu</surname><given-names>A</given-names></name><name name-style="western"><surname>Yigit</surname><given-names>S</given-names></name><name name-style="western"><surname>Tarhan</surname><given-names>MO</given-names></name></person-group><article-title>Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer</article-title><source>Pol J Pathol</source><year>2018</year><volume>69</volume><issue>2</issue><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">30351863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/pjp.2018.76699</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Kucukzeybek BB, Bayoglu IV, Kucukzeybek Y, Y&#305;ld&#305;z Y, Oflazoglu U, Atahan MK, Taskaynatan H, Alacacioglu A, Yigit S, Tarhan MO. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer. Pol J Pathol. 2018;69(2):157&#8211;68.<pub-id pub-id-type="pmid">30351863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/pjp.2018.76699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>A</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sharanappa</surname><given-names>V</given-names></name><name name-style="western"><surname>Krishnani</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>N</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>G</given-names></name></person-group><article-title>Incidence and prognostic significance of androgen receptors (AR) in Indian triple-negative breast cancer (TNBC)</article-title><source>Indian J Surg Oncol</source><year>2024</year><volume>15</volume><issue>2</issue><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">38741650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13193-024-01877-2</pub-id><pub-id pub-id-type="pmcid">PMC11088609</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Mishra A, Mishra SK, Sharanappa V, Krishnani N, Kumari N, Agarwal G. Incidence and prognostic significance of androgen receptors (AR) in Indian triple-negative breast cancer (TNBC). Indian J Surg Oncol. 2024;15(2):250&#8211;7.<pub-id pub-id-type="pmid">38741650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13193-024-01877-2</pub-id><pub-id pub-id-type="pmcid">PMC11088609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dieci</surname><given-names>MV</given-names></name><name name-style="western"><surname>Tsvetkova</surname><given-names>V</given-names></name><name name-style="western"><surname>Griguolo</surname><given-names>G</given-names></name><name name-style="western"><surname>Miglietta</surname><given-names>F</given-names></name><name name-style="western"><surname>Mantiero</surname><given-names>M</given-names></name><name name-style="western"><surname>Tasca</surname><given-names>G</given-names></name><name name-style="western"><surname>Cumerlato</surname><given-names>E</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>CA</given-names></name><name name-style="western"><surname>Giarratano</surname><given-names>T</given-names></name><name name-style="western"><surname>Faggioni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease</article-title><source>Front Oncol</source><year>2019</year><volume>9</volume><fpage>452</fpage><pub-id pub-id-type="pmid">31245286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2019.00452</pub-id><pub-id pub-id-type="pmcid">PMC6563384</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, et al. Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease. Front Oncol. 2019;9:452.<pub-id pub-id-type="pmid">31245286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2019.00452</pub-id><pub-id pub-id-type="pmcid">PMC6563384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinna</surname><given-names>N</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>YC</given-names></name><name name-style="western"><surname>Rida</surname><given-names>P</given-names></name></person-group><article-title>Kinesin family member C1 (KIFC1/HSET) underlies aggressive disease in androgen receptor-low and basal-like triple-negative breast cancers</article-title><source>Int J Mol Sci</source><year>2023</year><pub-id pub-id-type="pmid">38003261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242216072</pub-id><pub-id pub-id-type="pmcid">PMC10671256</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Jinna N, Yuan YC, Rida P. Kinesin family member C1 (KIFC1/HSET) underlies aggressive disease in androgen receptor-low and basal-like triple-negative breast cancers. Int J Mol Sci. 2023. 10.3390/ijms242216072.<pub-id pub-id-type="pmid">38003261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242216072</pub-id><pub-id pub-id-type="pmcid">PMC10671256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>BM</given-names></name><name name-style="western"><surname>El-Abhar</surname><given-names>HS</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>G</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>HR</given-names></name><name name-style="western"><surname>Aliedin</surname><given-names>N</given-names></name><name name-style="western"><surname>Sharaky</surname><given-names>M</given-names></name><name name-style="western"><surname>Shouman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>M</given-names></name></person-group><article-title>A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231</article-title><source>J Steroid Biochem Mol Biol</source><year>2025</year><volume>245</volume><fpage>106636</fpage><pub-id pub-id-type="pmid">39536950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2024.106636</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Ali BM, El-Abhar HS, Mohamed G, Nassar HR, Aliedin N, Sharaky M, Shouman SA, Kamel M. A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231. J Steroid Biochem Mol Biol. 2025;245: 106636.<pub-id pub-id-type="pmid">39536950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsbmb.2024.106636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anestis</surname><given-names>A</given-names></name><name name-style="western"><surname>Zoi</surname><given-names>I</given-names></name><name name-style="western"><surname>Papavassiliou</surname><given-names>AG</given-names></name><name name-style="western"><surname>Karamouzis</surname><given-names>MV</given-names></name></person-group><article-title>Androgen receptor in breast cancer-clinical and preclinical research insights</article-title><source>Molecules</source><year>2020</year><pub-id pub-id-type="pmid">31952272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25020358</pub-id><pub-id pub-id-type="pmcid">PMC7024330</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV. Androgen receptor in breast cancer-clinical and preclinical research insights. Molecules. 2020. 10.3390/molecules25020358.<pub-id pub-id-type="pmid">31952272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25020358</pub-id><pub-id pub-id-type="pmcid">PMC7024330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H</given-names></name></person-group><article-title>A comprehensive overview of small-molecule androgen receptor degraders: recent progress and future perspectives</article-title><source>J Med Chem</source><year>2022</year><volume>65</volume><issue>24</issue><fpage>16128</fpage><lpage>16154</lpage><pub-id pub-id-type="pmid">36459083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.2c01487</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Ha S, Luo G, Xiang H. A comprehensive overview of small-molecule androgen receptor degraders: recent progress and future perspectives. J Med Chem. 2022;65(24):16128&#8211;54.<pub-id pub-id-type="pmid">36459083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.2c01487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>LB</given-names></name><name name-style="western"><surname>Neklesa</surname><given-names>TK</given-names></name><name name-style="western"><surname>Willard</surname><given-names>RR</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pizzano</surname><given-names>J</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>N</given-names></name><name name-style="western"><surname>Robling</surname><given-names>K</given-names></name><name name-style="western"><surname>Dorso</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moghrabi</surname><given-names>W</given-names></name><name name-style="western"><surname>Landrette</surname><given-names>S</given-names></name><etal/></person-group><article-title>Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader</article-title><source>Mol Cancer Ther</source><year>2025</year><volume>24</volume><issue>4</issue><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">39670468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0655</pub-id><pub-id pub-id-type="pmcid">PMC11962395</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Snyder LB, Neklesa TK, Willard RR, Gordon DA, Pizzano J, Vitale N, Robling K, Dorso MA, Moghrabi W, Landrette S, et al. Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader. Mol Cancer Ther. 2025;24(4):511&#8211;22.<pub-id pub-id-type="pmid">39670468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0655</pub-id><pub-id pub-id-type="pmcid">PMC11962395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Targeting androgen receptor in glioblastoma</article-title><source>Crit Rev Oncol Hematol</source><year>2023</year><volume>191</volume><fpage>104142</fpage><pub-id pub-id-type="pmid">37742885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2023.104142</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Gan X, Liu Y, Wang X. Targeting androgen receptor in glioblastoma. Crit Rev Oncol Hematol. 2023;191: 104142.<pub-id pub-id-type="pmid">37742885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2023.104142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauman</surname><given-names>MC</given-names></name><name name-style="western"><surname>Won</surname><given-names>JH</given-names></name><name name-style="western"><surname>Petiwala</surname><given-names>SM</given-names></name><name name-style="western"><surname>Vemu</surname><given-names>B</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Sverdlov</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JJ</given-names></name></person-group><article-title>&#945;-mangostin promotes in vitro and in vivo degradation of androgen receptor and AR-V7 splice variant in prostate cancer cells</article-title><source>Cancers</source><year>2023</year><pub-id pub-id-type="pmid">37046780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15072118</pub-id><pub-id pub-id-type="pmcid">PMC10093438</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Nauman MC, Won JH, Petiwala SM, Vemu B, Lee H, Sverdlov M, Johnson JJ. &#945;-mangostin promotes in vitro and in vivo degradation of androgen receptor and AR-V7 splice variant in prostate cancer cells. Cancers. 2023. 10.3390/cancers15072118.<pub-id pub-id-type="pmid">37046780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15072118</pub-id><pub-id pub-id-type="pmcid">PMC10093438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundi</surname><given-names>D</given-names></name><name name-style="western"><surname>Collier</surname><given-names>KA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pohar</surname><given-names>KS</given-names></name><name name-style="western"><surname>Singer</surname><given-names>EA</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Carson</surname><given-names>WE</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Clinton</surname><given-names>SK</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Roles of androgen receptor signaling in urothelial carcinoma</article-title><source>Cancers</source><year>2024</year><pub-id pub-id-type="pmid">38398136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16040746</pub-id><pub-id pub-id-type="pmcid">PMC10886823</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Sundi D, Collier KA, Yang Y, Diaz DA, Pohar KS, Singer EA, Gupta S, Carson WE 3rd, Clinton SK, Li Z, et al. Roles of androgen receptor signaling in urothelial carcinoma. Cancers. 2024. 10.3390/cancers16040746.<pub-id pub-id-type="pmid">38398136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16040746</pub-id><pub-id pub-id-type="pmcid">PMC10886823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gucalp</surname><given-names>A</given-names></name><name name-style="western"><surname>Tolaney</surname><given-names>S</given-names></name><name name-style="western"><surname>Isakoff</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>JN</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MC</given-names></name><name name-style="western"><surname>Carey</surname><given-names>LA</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>K</given-names></name><name name-style="western"><surname>Rugo</surname><given-names>H</given-names></name><name name-style="western"><surname>Nabell</surname><given-names>L</given-names></name><name name-style="western"><surname>Forero</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>19</issue><fpage>5505</fpage><lpage>5512</lpage><pub-id pub-id-type="pmid">23965901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-12-3327</pub-id><pub-id pub-id-type="pmcid">PMC4086643</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505&#8211;12.<pub-id pub-id-type="pmid">23965901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-12-3327</pub-id><pub-id pub-id-type="pmcid">PMC4086643</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traina</surname><given-names>TA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K</given-names></name><name name-style="western"><surname>Yardley</surname><given-names>DA</given-names></name><name name-style="western"><surname>Eakle</surname><given-names>J</given-names></name><name name-style="western"><surname>Schwartzberg</surname><given-names>LS</given-names></name><name name-style="western"><surname>O'Shaughnessy</surname><given-names>J</given-names></name><name name-style="western"><surname>Gradishar</surname><given-names>W</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>P</given-names></name><name name-style="western"><surname>Winer</surname><given-names>E</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C</given-names></name><etal/></person-group><article-title>Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><issue>9</issue><fpage>884</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">29373071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.71.3495</pub-id><pub-id pub-id-type="pmcid">PMC5858523</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O&#8217;Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884&#8211;90.<pub-id pub-id-type="pmid">29373071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2016.71.3495</pub-id><pub-id pub-id-type="pmcid">PMC5858523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attard</surname><given-names>G</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>L</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>NW</given-names></name><name name-style="western"><surname>Cross</surname><given-names>W</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Parker</surname><given-names>CC</given-names></name><name name-style="western"><surname>Gillessen</surname><given-names>S</given-names></name><name name-style="western"><surname>Cook</surname><given-names>A</given-names></name><name name-style="western"><surname>Brawley</surname><given-names>C</given-names></name><name name-style="western"><surname>Amos</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol</article-title><source>Lancet</source><year>2022</year><volume>399</volume><issue>10323</issue><fpage>447</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">34953525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02437-5</pub-id><pub-id pub-id-type="pmcid">PMC8811484</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447&#8211;60.<pub-id pub-id-type="pmid">34953525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02437-5</pub-id><pub-id pub-id-type="pmcid">PMC8811484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnefoi</surname><given-names>H</given-names></name><name name-style="western"><surname>Grellety</surname><given-names>T</given-names></name><name name-style="western"><surname>Tredan</surname><given-names>O</given-names></name><name name-style="western"><surname>Saghatchian</surname><given-names>M</given-names></name><name name-style="western"><surname>Dalenc</surname><given-names>F</given-names></name><name name-style="western"><surname>Mailliez</surname><given-names>A</given-names></name><name name-style="western"><surname>L'Haridon</surname><given-names>T</given-names></name><name name-style="western"><surname>Cottu</surname><given-names>P</given-names></name><name name-style="western"><surname>Abadie-Lacourtoisie</surname><given-names>S</given-names></name><name name-style="western"><surname>You</surname><given-names>B</given-names></name><etal/></person-group><article-title>A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12&#8211;1)</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><issue>5</issue><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">27052658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw067</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L&#8217;Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12&#8211;1). Ann Oncol. 2016;27(5):812&#8211;8.<pub-id pub-id-type="pmid">27052658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnefoi</surname><given-names>H</given-names></name><name name-style="western"><surname>Lerebours</surname><given-names>F</given-names></name><name name-style="western"><surname>Pulido</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnedos</surname><given-names>M</given-names></name><name name-style="western"><surname>Tredan</surname><given-names>O</given-names></name><name name-style="western"><surname>Dalenc</surname><given-names>F</given-names></name><name name-style="western"><surname>Guiu</surname><given-names>S</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>L</given-names></name><name name-style="western"><surname>Mollon</surname><given-names>D</given-names></name><name name-style="western"><surname>Levy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3&#8211;06 START): a multicentre, non-comparative, randomised, phase 2 trial</article-title><source>Lancet Oncol</source><year>2025</year><volume>26</volume><issue>3</issue><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">39978376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(24)00737-X</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, Guiu S, Teixeira L, Mollon D, Levy C, et al. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3&#8211;06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2025;26(3):355&#8211;66.<pub-id pub-id-type="pmid">39978376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(24)00737-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>JC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Gu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Zou</surname><given-names>YP</given-names></name><name name-style="western"><surname>Li</surname><given-names>CC</given-names></name></person-group><article-title>Strategies and lessons learned from total synthesis of Taxol</article-title><source>Chem Rev</source><year>2023</year><volume>123</volume><issue>8</issue><fpage>4934</fpage><lpage>4971</lpage><pub-id pub-id-type="pmid">36917457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.2c00763</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Min L, Han JC, Zhang W, Gu CC, Zou YP, Li CC. Strategies and lessons learned from total synthesis of Taxol. Chem Rev. 2023;123(8):4934&#8211;71.<pub-id pub-id-type="pmid">36917457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.2c00763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosca</surname><given-names>L</given-names></name><name name-style="western"><surname>Ilari</surname><given-names>A</given-names></name><name name-style="western"><surname>Fazi</surname><given-names>F</given-names></name><name name-style="western"><surname>Assaraf</surname><given-names>YG</given-names></name><name name-style="western"><surname>Colotti</surname><given-names>G</given-names></name></person-group><article-title>Taxanes in cancer treatment: activity, chemoresistance and its overcoming</article-title><source>Drug Resist Updates</source><year>2021</year><volume>54</volume><fpage>100742</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drup.2020.100742</pub-id><pub-id pub-id-type="pmid">33429249</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updates. 2021;54: 100742.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drup.2020.100742</pub-id><pub-id pub-id-type="pmid">33429249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sousa-Pimenta</surname><given-names>M</given-names></name><name name-style="western"><surname>Estevinho</surname><given-names>LM</given-names></name><name name-style="western"><surname>Szopa</surname><given-names>A</given-names></name><name name-style="western"><surname>Basit</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K</given-names></name><name name-style="western"><surname>Armaghan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ibrayeva</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#246;nmez G&#252;rer</surname><given-names>E</given-names></name><name name-style="western"><surname>Calina</surname><given-names>D</given-names></name><name name-style="western"><surname>Hano</surname><given-names>C</given-names></name><etal/></person-group><article-title>Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1157306</fpage><pub-id pub-id-type="pmid">37229270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1157306</pub-id><pub-id pub-id-type="pmcid">PMC10203197</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, Ibrayeva M, S&#246;nmez G&#252;rer E, Calina D, Hano C, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306.<pub-id pub-id-type="pmid">37229270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1157306</pub-id><pub-id pub-id-type="pmcid">PMC10203197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>Y</given-names></name></person-group><article-title>Flubendazole enhances the inhibitory effect of Paclitaxel via HIF1&#945;/PI3K/AKT signaling pathways in breast cancer</article-title><source>Int J Mol Sci</source><year>2023</year><pub-id pub-id-type="pmid">37894802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242015121</pub-id><pub-id pub-id-type="pmcid">PMC10606573</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zhou Y, Liao M, Li Z, Ye J, Wu L, Mou Y, Fu L, Zhen Y. Flubendazole enhances the inhibitory effect of Paclitaxel via HIF1&#945;/PI3K/AKT signaling pathways in breast cancer. Int J Mol Sci. 2023. 10.3390/ijms242015121.<pub-id pub-id-type="pmid">37894802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242015121</pub-id><pub-id pub-id-type="pmcid">PMC10606573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Qu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells</article-title><source>Eur J Med Chem</source><year>2023</year><volume>250</volume><fpage>115218</fpage><pub-id pub-id-type="pmid">36871374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115218</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wang W, Wan Q, Li M, Qu F, Liu H, Chen Y. Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells. Eur J Med Chem. 2023;250: 115218.<pub-id pub-id-type="pmid">36871374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F</given-names></name></person-group><article-title>Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (review)</article-title><source>Int J Oncol</source><year>2023</year><pub-id pub-id-type="pmid">37654171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2023.5567</pub-id><pub-id pub-id-type="pmcid">PMC10546381</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (review). Int J Oncol. 2023. 10.3892/ijo.2023.5567.<pub-id pub-id-type="pmid">37654171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2023.5567</pub-id><pub-id pub-id-type="pmcid">PMC10546381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyshlovoy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shubina</surname><given-names>LK</given-names></name><name name-style="western"><surname>Makarieva</surname><given-names>TN</given-names></name><name name-style="western"><surname>Hauschild</surname><given-names>J</given-names></name><name name-style="western"><surname>Strewinsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Guzii</surname><given-names>AG</given-names></name><name name-style="western"><surname>Menshov</surname><given-names>AS</given-names></name><name name-style="western"><surname>Popov</surname><given-names>RS</given-names></name><name name-style="western"><surname>Grebnev</surname><given-names>BB</given-names></name><name name-style="western"><surname>Busenbender</surname><given-names>T</given-names></name><etal/></person-group><article-title>New diterpenes from the marine sponge <italic toggle="yes">Spongionella</italic> sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>13570</fpage><pub-id pub-id-type="pmid">35945234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-17447-x</pub-id><pub-id pub-id-type="pmcid">PMC9363487</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Dyshlovoy SA, Shubina LK, Makarieva TN, Hauschild J, Strewinsky N, Guzii AG, Menshov AS, Popov RS, Grebnev BB, Busenbender T, et al. New diterpenes from the marine sponge <italic toggle="yes">Spongionella</italic> sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein. Sci Rep. 2022;12(1):13570.<pub-id pub-id-type="pmid">35945234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-17447-x</pub-id><pub-id pub-id-type="pmcid">PMC9363487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Enhancing paclitaxel efficacy with piperine-paclitaxel albumin nanoparticles in multidrug-resistant triple-negative breast cancer by inhibiting P-glycoprotein</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>12</issue><fpage>2703</fpage><pub-id pub-id-type="pmid">38140044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15122703</pub-id><pub-id pub-id-type="pmcid">PMC10747290</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Xu W, Xiao Y, Zheng L, Xu M, Jiang X, Wang L. Enhancing paclitaxel efficacy with piperine-paclitaxel albumin nanoparticles in multidrug-resistant triple-negative breast cancer by inhibiting P-glycoprotein. Pharmaceutics. 2023;15(12):2703.<pub-id pub-id-type="pmid">38140044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15122703</pub-id><pub-id pub-id-type="pmcid">PMC10747290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>SR</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagarajan</surname><given-names>P</given-names></name><name name-style="western"><surname>Amit</surname><given-names>M</given-names></name></person-group><article-title>Nerve density and neuronal biomarkers in cancer</article-title><source>Cancers</source><year>2022</year><pub-id pub-id-type="pmid">36230740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14194817</pub-id><pub-id pub-id-type="pmcid">PMC9561962</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Ali SR, Jordan M, Nagarajan P, Amit M. Nerve density and neuronal biomarkers in cancer. Cancers. 2022. 10.3390/cancers14194817.<pub-id pub-id-type="pmid">36230740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14194817</pub-id><pub-id pub-id-type="pmcid">PMC9561962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>B</given-names></name><name name-style="western"><surname>Seth</surname><given-names>S</given-names></name><name name-style="western"><surname>Yam</surname><given-names>C</given-names></name><name name-style="western"><surname>Huo</surname><given-names>L</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Bassett</surname><given-names>R</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>S</given-names></name><name name-style="western"><surname>Ravenberg</surname><given-names>L</given-names></name><name name-style="western"><surname>White</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into "ARness"</article-title><source>Cell Rep Med</source><year>2024</year><volume>5</volume><issue>6</issue><fpage>101595</fpage><pub-id pub-id-type="pmid">38838676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2024.101595</pub-id><pub-id pub-id-type="pmcid">PMC11228653</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, et al. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into &#8220;ARness.&#8221; Cell Rep Med. 2024;5(6): 101595.<pub-id pub-id-type="pmid">38838676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2024.101595</pub-id><pub-id pub-id-type="pmcid">PMC11228653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michmerhuizen</surname><given-names>AR</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Ward</surname><given-names>C</given-names></name><name name-style="western"><surname>Pesch</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>R</given-names></name><name name-style="western"><surname>Wilder-Romans</surname><given-names>K</given-names></name><name name-style="western"><surname>Eisner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Rae</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><issue>5</issue><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">35618789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-022-01849-9</pub-id><pub-id pub-id-type="pmcid">PMC9427858</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Michmerhuizen AR, Lerner LM, Ward C, Pesch AM, Zhang A, Schwartz R, Wilder-Romans K, Eisner JR, Rae JM, Pierce LJ, et al. Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. Br J Cancer. 2022;127(5):927&#8211;36.<pub-id pub-id-type="pmid">35618789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-022-01849-9</pub-id><pub-id pub-id-type="pmcid">PMC9427858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dear</surname><given-names>RF-G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cosman</surname><given-names>R</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>N</given-names></name><name name-style="western"><surname>Selga</surname><given-names>M</given-names></name><name name-style="western"><surname>Perez San Juan</surname><given-names>B</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>C</given-names></name><name name-style="western"><surname>Chaffer</surname><given-names>CL</given-names></name></person-group><article-title>4CAST: a phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2024</year><volume>42</volume><issue>16_suppl</issue><fpage>e13112</fpage><lpage>e13112</lpage></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Dear RF-G, Liu J, Cosman R, Walsh N, Selga M, Perez San Juan B, Purcell C, Chaffer CL. 4CAST: a phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 2024;42(16_suppl):e13112&#8211;e13112.</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>P</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><issue>12</issue><fpage>1052</fpage><pub-id pub-id-type="pmid">33311440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-03235-w</pub-id><pub-id pub-id-type="pmcid">PMC7733521</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, et al. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020;11(12):1052.<pub-id pub-id-type="pmid">33311440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-03235-w</pub-id><pub-id pub-id-type="pmcid">PMC7733521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qing</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K</article-title><source>Biochem Pharmacol</source><year>2024</year><volume>226</volume><fpage>116408</fpage><pub-id pub-id-type="pmid">38969297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2024.116408</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Wang R, Jia S, Chen H, Luo K, Zhang L, Song Y, Qing C, Liu D, Zhou H. Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K. Biochem Pharmacol. 2024;226: 116408.<pub-id pub-id-type="pmid">38969297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2024.116408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coussy</surname><given-names>F</given-names></name><name name-style="western"><surname>Lavigne</surname><given-names>M</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>L</given-names></name><name name-style="western"><surname>Botty</surname><given-names>RE</given-names></name><name name-style="western"><surname>Nemati</surname><given-names>F</given-names></name><name name-style="western"><surname>Naguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Bataillon</surname><given-names>G</given-names></name><name name-style="western"><surname>Ouine</surname><given-names>B</given-names></name><name name-style="western"><surname>Dahmani</surname><given-names>A</given-names></name><name name-style="western"><surname>Montaudon</surname><given-names>E</given-names></name><etal/></person-group><article-title>Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>1531</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">32042320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.36182</pub-id><pub-id pub-id-type="pmcid">PMC6993232</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, Bataillon G, Ouine B, Dahmani A, Montaudon E, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10(4):1531&#8211;43.<pub-id pub-id-type="pmid">32042320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.36182</pub-id><pub-id pub-id-type="pmcid">PMC6993232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Bal</surname><given-names>A</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Loriya</surname><given-names>I</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name></person-group><article-title>Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2021</year><volume>187</volume><issue>3</issue><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">33954864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-021-06242-3</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Kumar S, Bal A, Das A, Loriya I, Khare S, Bhattacharya S, Singh G. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Breast Cancer Res Treat. 2021;187(3):625&#8211;33.<pub-id pub-id-type="pmid">33954864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-021-06242-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Fuson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwase</surname><given-names>T</given-names></name><name name-style="western"><surname>Yun</surname><given-names>K</given-names></name><name name-style="western"><surname>Margain</surname><given-names>C</given-names></name><name name-style="western"><surname>Tripathy</surname><given-names>D</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>NT</given-names></name></person-group><article-title>Identification of kinase targets for enhancing the antitumor activity of eribulin in triple-negative breast cell lines</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>3</issue><fpage>735</fpage><pub-id pub-id-type="pmid">36979714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11030735</pub-id><pub-id pub-id-type="pmcid">PMC10045293</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Xie X, Lee J, Fuson JA, Liu H, Iwase T, Yun K, Margain C, Tripathy D, Ueno NT. Identification of kinase targets for enhancing the antitumor activity of eribulin in triple-negative breast cell lines. Biomedicines. 2023;11(3):735.<pub-id pub-id-type="pmid">36979714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11030735</pub-id><pub-id pub-id-type="pmcid">PMC10045293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>BD</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>VG</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>EL</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>TC</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>R</given-names></name><name name-style="western"><surname>Van Poznak</surname><given-names>C</given-names></name><name name-style="western"><surname>Storniolo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nangia</surname><given-names>JR</given-names></name><name name-style="western"><surname>Gonzalez-Ericsson</surname><given-names>PI</given-names></name><etal/></person-group><article-title>TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer</article-title><source>Clin Cancer Res</source><year>2020</year><volume>26</volume><issue>9</issue><fpage>2111</fpage><lpage>2123</lpage><pub-id pub-id-type="pmid">31822498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-2170</pub-id><pub-id pub-id-type="pmcid">PMC7196503</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26(9):2111&#8211;23.<pub-id pub-id-type="pmid">31822498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-2170</pub-id><pub-id pub-id-type="pmcid">PMC7196503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karuturi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuji</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>N</given-names></name></person-group><article-title>Abstract 4693: a Phase 1b study of BYL719 (Alpelisib) in combination with androgen receptor inhibitor (enzalutamide) in patients with androgen receptor (AR)-positive and PTEN-positive metastatic breast cancer</article-title><source>Cancer Res</source><year>2024</year><volume>84</volume><issue>6_Suppl</issue><fpage>4693</fpage><lpage>4693</lpage></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Karuturi M, Fuji T, Ueno N. Abstract 4693: a Phase 1b study of BYL719 (Alpelisib) in combination with androgen receptor inhibitor (enzalutamide) in patients with androgen receptor (AR)-positive and PTEN-positive metastatic breast cancer. Cancer Res. 2024;84(6_Suppl):4693&#8211;4693.</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choupani</surname><given-names>E</given-names></name><name name-style="western"><surname>Madjd</surname><given-names>Z</given-names></name><name name-style="western"><surname>Saraygord-Afshari</surname><given-names>N</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>J</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>A</given-names></name></person-group><article-title>Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>12</issue><fpage>e0279522</fpage><pub-id pub-id-type="pmid">36548336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0279522</pub-id><pub-id pub-id-type="pmcid">PMC9779032</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Choupani E, Madjd Z, Saraygord-Afshari N, Kiani J, Hosseini A. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells. PLoS ONE. 2022;17(12): e0279522.<pub-id pub-id-type="pmid">36548336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0279522</pub-id><pub-id pub-id-type="pmcid">PMC9779032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serhan</surname><given-names>HA</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Heth</surname><given-names>JA</given-names></name><name name-style="western"><surname>Udager</surname><given-names>AM</given-names></name><name name-style="western"><surname>Soellner</surname><given-names>MB</given-names></name><name name-style="western"><surname>Merajver</surname><given-names>SD</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion</article-title><source>NPJ Breast Cancer</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>43</fpage><pub-id pub-id-type="pmid">38858374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-024-00656-0</pub-id><pub-id pub-id-type="pmcid">PMC11164988</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Serhan HA, Bao L, Cheng X, Qin Z, Liu CJ, Heth JA, Udager AM, Soellner MB, Merajver SD, Morikawa A, et al. Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. NPJ Breast Cancer. 2024;10(1):43.<pub-id pub-id-type="pmid">38858374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-024-00656-0</pub-id><pub-id pub-id-type="pmcid">PMC11164988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gucalp</surname><given-names>A</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>LA</given-names></name><name name-style="western"><surname>Alano</surname><given-names>T</given-names></name><name name-style="western"><surname>Arumov</surname><given-names>A</given-names></name><name name-style="western"><surname>Gounder</surname><given-names>MM</given-names></name><name name-style="western"><surname>Patil</surname><given-names>S</given-names></name><name name-style="western"><surname>Feigin</surname><given-names>K</given-names></name><name name-style="western"><surname>Edelweiss</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>G</given-names></name><name name-style="western"><surname>Bromberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15_suppl</issue><fpage>1017</fpage><lpage>1017</lpage></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Gucalp A, Boyle LA, Alano T, Arumov A, Gounder MM, Patil S, Feigin K, Edelweiss M, D&#8217;Andrea G, Bromberg J, et al. Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. J Clin Oncol. 2020;38(15_suppl):1017&#8211;1017.</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>SU</given-names></name><name name-style="western"><surname>Sham</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaire</surname><given-names>B</given-names></name><name name-style="western"><surname>Vancura</surname><given-names>A</given-names></name><name name-style="western"><surname>Vancurova</surname><given-names>I</given-names></name></person-group><article-title>Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3 and STAT1 in ovarian cancer cells</article-title><source>J Biol Chem</source><year>2025</year><volume>301</volume><fpage>108339</fpage><pub-id pub-id-type="pmid">39988077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2025.108339</pub-id><pub-id pub-id-type="pmcid">PMC11982968</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Reddy SU, Sham R, Smith K, Gaire B, Vancura A, Vancurova I. Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3 and STAT1 in ovarian cancer cells. J Biol Chem. 2025;301:108339.<pub-id pub-id-type="pmid">39988077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2025.108339</pub-id><pub-id pub-id-type="pmcid">PMC11982968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>BG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WY</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SI</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SC</given-names></name></person-group><article-title>Cannabidiol enhances atezolizumab efficacy by upregulating PD-L1 expression via the cGAS-STING pathway in triple-negative breast cancer cells</article-title><source>Cancer Immunol Res</source><year>2024</year><volume>12</volume><issue>12</issue><fpage>1796</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">39226389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-23-0902</pub-id><pub-id pub-id-type="pmcid">PMC11612622</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Kim BG, Kim BR, Kim DY, Kim WY, Kang S, Lee SI, Oh SC. Cannabidiol enhances atezolizumab efficacy by upregulating PD-L1 expression via the cGAS-STING pathway in triple-negative breast cancer cells. Cancer Immunol Res. 2024;12(12):1796&#8211;807.<pub-id pub-id-type="pmid">39226389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-23-0902</pub-id><pub-id pub-id-type="pmcid">PMC11612622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tumor-derived extracellular vesicles enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><issue>45</issue><fpage>30943</fpage><lpage>30956</lpage><pub-id pub-id-type="pmid">39474658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c12967</pub-id><pub-id pub-id-type="pmcid">PMC11562804</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Peng Z, Zhao T, Gao P, Zhang G, Wu X, Tian H, Qu M, Tan X, Zhang Y, Zhao X, et al. Tumor-derived extracellular vesicles enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer. ACS Nano. 2024;18(45):30943&#8211;56.<pub-id pub-id-type="pmid">39474658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c12967</pub-id><pub-id pub-id-type="pmcid">PMC11562804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>You</surname><given-names>R</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shan</surname><given-names>T</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Combination nano-delivery systems remodel the immunosuppressive tumor microenvironment for metastatic triple-negative breast cancer therapy</article-title><source>Mol Pharm</source><year>2024</year><volume>21</volume><issue>5</issue><fpage>2148</fpage><lpage>2162</lpage><pub-id pub-id-type="pmid">38536949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.3c00242</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Bai L, Liu H, You R, Jiang X, Zhang T, Li Y, Shan T, Qian Z, Wang Y, Liu Y, et al. Combination nano-delivery systems remodel the immunosuppressive tumor microenvironment for metastatic triple-negative breast cancer therapy. Mol Pharm. 2024;21(5):2148&#8211;62.<pub-id pub-id-type="pmid">38536949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.3c00242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medi&#263;-Miliji&#263;</surname><given-names>N</given-names></name><name name-style="western"><surname>Jovani&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Nedeljkovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Markovi&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Spurni&#263;</surname><given-names>I</given-names></name><name name-style="western"><surname>Milovanovi&#263;</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ademovi&#263;</surname><given-names>N</given-names></name><name name-style="western"><surname>Tomi&#263;</surname><given-names>T</given-names></name><name name-style="western"><surname>Tani&#263;</surname><given-names>N</given-names></name><name name-style="western"><surname>Tani&#263;</surname><given-names>N</given-names></name></person-group><article-title>Prognostic and clinical significance of PD-L1, EGFR and androgen receptor (AR) expression in triple-negative breast cancer (TNBC) patients</article-title><source>Life</source><year>2024</year><volume>14</volume><issue>6</issue><fpage>682</fpage><pub-id pub-id-type="pmid">38929666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life14060682</pub-id><pub-id pub-id-type="pmcid">PMC11205209</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Medi&#263;-Miliji&#263; N, Jovani&#263; I, Nedeljkovi&#263; M, Markovi&#263; I, Spurni&#263; I, Milovanovi&#263; Z, Ademovi&#263; N, Tomi&#263; T, Tani&#263; N, Tani&#263; N. Prognostic and clinical significance of PD-L1, EGFR and androgen receptor (AR) expression in triple-negative breast cancer (TNBC) patients. Life. 2024;14(6):682.<pub-id pub-id-type="pmid">38929666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life14060682</pub-id><pub-id pub-id-type="pmcid">PMC11205209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yost</surname><given-names>SE</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>PH</given-names></name><name name-style="western"><surname>Ruel</surname><given-names>C</given-names></name><name name-style="western"><surname>Egelston</surname><given-names>CA</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Gillece</surname><given-names>JD</given-names></name><name name-style="western"><surname>Folkerts</surname><given-names>M</given-names></name><name name-style="western"><surname>Reining</surname><given-names>L</given-names></name><etal/></person-group><article-title>A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><issue>2</issue><fpage>99</fpage><lpage>e217</lpage><pub-id pub-id-type="pmid">33141975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/onco.13583</pub-id><pub-id pub-id-type="pmcid">PMC7873338</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Gillece JD, Folkerts M, Reining L, et al. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist. 2021;26(2):99-e217.<pub-id pub-id-type="pmid">33141975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/onco.13583</pub-id><pub-id pub-id-type="pmcid">PMC7873338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><etal/></person-group><article-title>The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>1015</fpage><pub-id pub-id-type="pmid">38310192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45160-y</pub-id><pub-id pub-id-type="pmcid">PMC10838317</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Li Q, Liu J, Zhang Q, Ouyang Q, Zhang Y, Liu Q, Sun T, Ye F, Zhang B, Xia S, et al. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nat Commun. 2024;15(1):1015.<pub-id pub-id-type="pmid">38310192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-45160-y</pub-id><pub-id pub-id-type="pmcid">PMC10838317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lai</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer</article-title><source>Oncol Lett</source><year>2023</year><volume>25</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="pmid">36589669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2022.13619</pub-id><pub-id pub-id-type="pmcid">PMC9773322</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Zhu M, Liu N, Lin J, Wang J, Lai H, Liu Y. HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer. Oncol Lett. 2023;25(1):33.<pub-id pub-id-type="pmid">36589669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2022.13619</pub-id><pub-id pub-id-type="pmcid">PMC9773322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Histone deacetylase 6 in cancer</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><issue>1</issue><fpage>111</fpage><pub-id pub-id-type="pmid">30176876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-018-0654-9</pub-id><pub-id pub-id-type="pmcid">PMC6122547</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, Zhang W, Yang J. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11(1):111.<pub-id pub-id-type="pmid">30176876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-018-0654-9</pub-id><pub-id pub-id-type="pmcid">PMC6122547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YM</given-names></name><name name-style="western"><surname>Liou</surname><given-names>JP</given-names></name></person-group><article-title>An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present)</article-title><source>Expert Opin Ther Pat</source><year>2023</year><volume>33</volume><issue>5</issue><fpage>349</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">37249104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543776.2023.2219393</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Liu YM, Liou JP. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present). Expert Opin Ther Pat. 2023;33(5):349&#8211;69.<pub-id pub-id-type="pmid">37249104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543776.2023.2219393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ji</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name></person-group><article-title>Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review</article-title><source>Eur J Med Chem</source><year>2025</year><volume>283</volume><fpage>117185</fpage><pub-id pub-id-type="pmid">39709797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.117185</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Lv Z, Ji T, Liu J, Sun X, Liang H. Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review. Eur J Med Chem. 2025;283: 117185.<pub-id pub-id-type="pmid">39709797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.117185</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caligiuri</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>GL</given-names></name><name name-style="western"><surname>Castro</surname><given-names>J</given-names></name><name name-style="western"><surname>Battalagine</surname><given-names>L</given-names></name><name name-style="western"><surname>Wilker</surname><given-names>E</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>S</given-names></name><name name-style="western"><surname>Toms</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>E</given-names></name><etal/></person-group><article-title>FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer</article-title><source>Target Oncol</source><year>2023</year><volume>18</volume><issue>2</issue><fpage>269</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">36826464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11523-023-00949-7</pub-id><pub-id pub-id-type="pmcid">PMC10042772</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Caligiuri M, Williams GL, Castro J, Battalagine L, Wilker E, Yao L, Schiller S, Toms A, Li P, Pardo E, et al. FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer. Target Oncol. 2023;18(2):269&#8211;85.<pub-id pub-id-type="pmid">36826464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11523-023-00949-7</pub-id><pub-id pub-id-type="pmcid">PMC10042772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>K</given-names></name></person-group><article-title>Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1164514</fpage><pub-id pub-id-type="pmid">36969235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1164514</pub-id><pub-id pub-id-type="pmcid">PMC10034161</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Lian B, Chen X, Shen K. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. Front Immunol. 2023;14:1164514.<pub-id pub-id-type="pmid">36969235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1164514</pub-id><pub-id pub-id-type="pmcid">PMC10034161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="pmid">38182579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-06303-z</pub-id><pub-id pub-id-type="pmcid">PMC10770036</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Zhu Q, Dai Q, Zhao L, Zheng C, Li Q, Yuan Z, Li L, Xie Z, Qiu Z, Huang W, et al. Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer. Cell Death Dis. 2024;15(1):10.<pub-id pub-id-type="pmid">38182579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-06303-z</pub-id><pub-id pub-id-type="pmcid">PMC10770036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name></person-group><article-title>HDAC inhibitors: promising agents for leukemia treatment</article-title><source>Biochem Biophys Res Commun</source><year>2023</year><volume>680</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">37722346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2023.09.023</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Deng Y, Cheng Q, He J. HDAC inhibitors: promising agents for leukemia treatment. Biochem Biophys Res Commun. 2023;680:61&#8211;72.<pub-id pub-id-type="pmid">37722346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2023.09.023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uba</surname><given-names>AI</given-names></name><name name-style="western"><surname>Zengin</surname><given-names>G</given-names></name></person-group><article-title>In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods</article-title><source>Amino Acids</source><year>2023</year><volume>55</volume><issue>12</issue><fpage>1709</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">37367966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00726-023-03297-y</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Uba AI, Zengin G. In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods. Amino Acids. 2023;55(12):1709&#8211;26.<pub-id pub-id-type="pmid">37367966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00726-023-03297-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name></person-group><article-title>HDAC inhibitors target IRS4 to enhance anti-AR therapy in AR-positive triple-negative breast cancer</article-title><source>Int J Oncol</source><year>2024</year><volume>64</volume><issue>3</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">38214343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2024.5613</pub-id><pub-id pub-id-type="pmcid">PMC10807637</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">He Y, Ma Y, Zhu Y, Zhang J, Zhao S, Zhang D, Xu D, Li Y, Tong Z, Zhao W. HDAC inhibitors target IRS4 to enhance anti-AR therapy in AR-positive triple-negative breast cancer. Int J Oncol. 2024;64(3):1&#8211;3.<pub-id pub-id-type="pmid">38214343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2024.5613</pub-id><pub-id pub-id-type="pmcid">PMC10807637</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>